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ABSTRACT 
Justin Layne Black: Exploration of the role of CIB1 in cell survival and tumor growth 
(Under the direction of Leslie V. Parise) 
 
CIB1 is an intracellular protein with diverse functions in cancer cell biology. Here I explore 
two important functions of CIB1: 1) The role of CIB1 in cell survival and tumor growth in triple 
negative breast cancer; and 2) The interaction between CIB1 and α-integrin cytoplasmic tails and 
the role of this interaction in cell biology. 
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with an 
unmet need for novel targeted therapeutics. We previously demonstrated that CIB1 is necessary 
for cancer cell survival and proliferation via regulation of two oncogenic signaling pathways, RAS-
RAF-MEK-ERK and PI3K-AKT. Because these pathways are often upregulated in TNBC, we 
hypothesized that CIB1 may play a broader role in TNBC cell survival and tumor growth.  Here 
we find that CIB1 is necessary for cell survival in multiple TNBC cell lines in vitro, and TNBC 
xenograft tumor growth in vivo. Furthermore, elevated AKT activation status and low PTEN 
expression were key predictors of sensitivity to CIB1 depletion in TNBC cells. Importantly, CIB1 
knockdown caused dramatic shrinkage of MDA-MB-468 xenograft tumors in vivo. RNA sequence 
analysis showed that CIB1 depletion activates gene programs associated with decreased 
proliferation and increased cell death. Taken together, our data are consistent with the emerging 
theory of non-oncogene addiction, where a large subset of TNBCs depend on CIB1 for cell 
survival and tumor growth, independent of CIB1 expression levels.  
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Integrins are heterodimeric transmembrane receptors important for cell adhesion to the 
extracellular matrix and transmission of signals through the cell membrane. Integrins are 
regulated via binding of cytoplasmic proteins to the integrin cytoplasmic tail. CIB1 was discovered 
as a binding partner of one integrin, αIIb, but the role of CIB1 in binding and regulating additional 
integrins was previously unknown. Here I also present evidence that CIB1 interacts with integrin 
αV via residues in the transmembrane portion of the integrin, can access these residues in the 
presence of a cell membrane, and that CIB1-integrin binding may contribute to cell signaling and 
proliferation. In summary, CIB1 is a diverse protein with important functions in TNBC cell survival 
and proliferation, as well as integrin biology.   
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CHAPTER 1: AN INTRODUCTION 
 
1.1 Cancer Introduction 
Cancer is the second leading cause of death worldwide, with over 12 million new 
diagnoses and more than 7 million deaths attributed to cancer in 2008 (1). Cancer is a 
heterogeneous group of diseases in which normal cells become transformed and exhibit 
uncontrolled growth (2). At the molecular level, cancer is driven by genetic mutations resulting in 
activation of oncogenes or inactivation of tumor suppressor genes (the concept of oncogenes and 
tumor suppressor genes has been reviewed extensively – a few helpful and relevant references 
may be found here (2-7)). These events lead to unchecked cell proliferation and survival resulting 
in tumor formation and, eventually, metastasis to foreign tissue sites and patient death (Figure 1-
1) (8,9). Cancer therapy presents significant challenges for physicians, and there is an unmet 
need for targeted treatments with improved efficacy and safety profiles.  
Here I will review one particular cancer subtype, triple negative breast cancer (TNBC), 
then describe cancer at the cellular and molecular level with a focus on oncogenic signaling 
pathways and their contribution to TNBC. 
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Figure 1-1. Cancer genesis. Normal cells experience a genetic mutation resulting in increased 
proliferation forming a primary tumor. Eventually tumor cells detach from the primary tumor site 
and metastasize to foreign tissues. 
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1.1.1 Triple negative breast cancer 
Breast cancer is diagnosed in more than 230,000 women each year in the United States 
(10), and is the leading cause of cancer-related deaths among women worldwide (1). 
Approximately 15 percent of breast cancers are a subtype called triple negative breast cancer 
(TNBC), defined by lack of expression of three receptors: estrogen receptor (ER); progesterone 
receptor, and human epidermal growth factor receptor 2 (HER2) (11). TNBC is an aggressive 
cancer subtype with generally poor prognosis. Targeted treatments are used for ER-positive (e.g. 
Tamoxifen) and HER2-positive (e.g. Herceptin) breast cancers. These targeted treatments 
improve overall survival for patients with these sub-types (12). However, no targeted therapies 
are currently approved for TNBC (13). Although TNBC is sensitive to chemotherapy, the overall 
prognosis in TNBC is worse than non-TNBC sub-types due to high rates of relapse. TNBC 
patients also have a shorter overall survival rate relative to other breast cancer subtypes (14). 
Ongoing research has explored novel targets for TNBC therapy, and several targeted agents 
have progressed into clinical trials. However, there remains an unmet need for new targeted 
therapeutics with improved safety and efficacy to improve TNBC patient outcomes. 
 
1.1.2 PI3K-AKT and RAS-RAF-MEK-ERK cancer signaling pathways 
Cancer is caused by genetic alterations that lead to uncontrolled cell survival and 
proliferation. Genetic mutations typically lead to a nonfunctional gene product, which, if 
deleterious, is recognized by the cell and can lead to programmed cell death, an evolutionary 
mechanism through which a single cell self-destructs for the good of the greater organism (15). 
However, occasionally a genetic mutation may lead a cell to undergo transformation such that it 
begins proliferating uncontrollably, resulting in tumor formation (15). Gain of function mutations 
or amplification of oncogenes, and loss of function mutations or deletion of tumor suppressor 
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genes, often result in unrestrained activation of oncogenic signaling pathways. Several commonly 
mutated genes resulting in aberrant oncogenic signaling include PIK3CA, BRAF, KRAS, PTEN, 
and NRAS (see Table 1-1) (16). These particular mutations result in aberrant activation of PI3K-
AKT and RAS-RAF-MEK-ERK, two commonly activated oncogenic signaling pathways in TNBC 
that are pertinent to the data presented herein (17). Cross-talk between these pathways enables 
cancer cells to compensate for inhibition of one pathway by activating the other pathway (17,18).  
 
Table 1-1. Commonly mutated cancer genes. Selected genes from a list of the most commonly 
mutated cancer genes. See Lawrence et al. for complete list (16). 
 
Aberrant activation of the RAS-RAF-MEK-ERK signaling pathway leads to unrestrained 
cell survival and proliferation. The RAS oncogene is one of the most commonly mutated genes in 
cancer (reportedly mutated in ~30% of all cancers) and the RAS signaling pathways have 
frequently been cited as targets for cancer therapy (19-21). Despite significant effort, scientists 
and drug developers have been unsuccessful at developing small molecule inhibitors of RAS, 
although recent advances in siRNA delivery technology may offer an effective alternative 
approach (22). However, RAS mutations are rare in TNBC (23). Several studies, including the 
Gene name Protein name 
Oncogene/ Tumor 
Suppressor 
PIK3CA 
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic 
subunit alpha Oncogene 
BRAF V-Raf murine sarcoma viral oncogene homolog B1 Oncogene 
KRAS V-KI-Ras2 Kirsten rat sarcoma viral oncogene homolog Oncogene 
PTEN Phosphatase and tensin homolog Tumor Suppressor 
NRAS Neuroblastoma ras viral oncogene homolog Oncogene 
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Cancer Genome Atlas study, reported RAS mutations in less than two percent of all breast 
cancers (24-26). In addition to RAS mutations, RAF is commonly mutated in cancer and also 
contributes to activation of MEK-ERK signaling and cell proliferation (27).  
Although RAS mutations are rare in breast cancer, mutations activating PI3K-AKT 
signaling are more common in breast cancer, including activating PI3K mutations and inactivating 
mutations to PTEN. One cause of aberrant PI3K-AKT activation involves the catalytic subunit of 
PI3K, PIK3CA, which is mutated in up to 30% of epithelial cancers, including breast, colon, 
prostate, and endometrial cancers (28). Another common mutation leading to PI3K-AKT activation 
is mutation, deletion, or downregulation of the tumor suppressor PTEN (phosphatase and tensin 
homolog deleted on chromosome 10), a lipid/protein phosphatase that inactivates PI3K signaling 
via dephosphorylation of the lipid PIP3 (phosphatidylinositol-3,4,5-triphosphate) (29). PIP3 has 
an important role in PI3K-AKT pathway activation by binding PDK1 and promoting PDK1-
dependent phosphorylation of AKT. PTEN inhibits the PI3K-PIP3-PDK1-AKT pathway by 
dephosphorylating PIP3 to PIP2 (Figure 1-2) (30-33). Therefore, PTEN functions as a clinically-
relevant tumor suppressor by putting the molecular brakes on PI3K-AKT activation. In a recent 
study of breast cancer patients, PTEN expression negatively correlated with tumor size, 
suggesting that loss of PTEN may be an important driver of tumor growth (34). PTEN 
mutations/deletions also lead to a higher incidence of tumor formation in mice and humans 
(35,36). 
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Figure 1-2. PTEN inhibits PI3K activation of PDK1 by dephosphorylating PIP3. PI3K 
catalyzes the phosphorylation of PIP2 to PIP3. PIP3 binding to PDK1 is necessary for PDK1 
phosphorylation and activation of AKT. PTEN inhibits PI3K-PDK1-AKT activation by 
dephosphorylating PIP3. 
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Due to the clinical relevance and the high rate of mutation in the PI3K-AKT and RAS-RAF-
MEK-ERK signaling pathways, extensive work has been done to characterize these 
genes/pathways. Here I briefly summarize some of the relevant elements of these two important 
signaling cascades. Both RAS and PI3K signaling are stimulated by receptor tyrosine kinase 
(RTK) activation (28,37). For example, epidermal growth factor receptors (EGFR) are bound by 
extracellular epidermal growth factor (EGF), stimulating a conformational change and activation 
of EGFR. Active EGFR phosphorylates and activates its substrates, such as PI3K. PI3K 
stimulates activation of PDK1 via PIP3, leading to AKT activation as well as downstream activities 
including cell survival, cell proliferation, and gene expression (see Figure 1-5). PI3K activity is 
inhibited by the phosphatase PTEN. Cells harboring PTEN mutations or PTEN deficiency exhibit 
activated PI3K signaling, leading to uncontrolled cell survival and growth.  
 
1.1.3 Challenges of inhibiting PI3K and RAS pathways clinically 
Inhibitors targeting PI3K, AKT, RAF, and MEK have been tested in clinical studies, with 
unexceptional efficacy and safety profiles. Here I will briefly review these pathway inhibitors and 
some of the challenges inhibiting their development. RAF inhibitors have proven to be effective 
only in BRAF-mutant cancers (e.g. BRAFV600E-mutant melanoma) but not in cancers with active 
RAS-RAF-MEK-ERK driven by other mutations (38). Similarly, MEK inhibitors have had limited 
efficacy in clinical trials when used as single-agent therapies (39). At least thirteen individual MEK 
inhibitors have been tested clinically, but only one (Trametinib, GlaxoSmithKline) has shown 
clinical efficacy and received FDA approval. Like RAF inhibitors, Trametinib is indicated only for 
patients with BRAF-mutated melanoma (40,41). 
PI3K inhibitors have acceptable safety when used as monotherapy, but only modest 
antitumor effects (42), and of the 21 PI3K inhibitors in clinical trials, just one (Idelalisib, Gilead 
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Sciences) has received FDA approval for several indications in leukemia and lymphoma (43,44). 
PI3K inhibitors are likely to be most effective when used in combination with other inhibitors (i.e. 
chemotherapy, RTK inhibitors, and MEK inhibitors) (45,46). AKT inhibitors are also being 
developed and have demonstrated promising efficacy, but also have some safety concerns 
including skin rashes and hyperglycemia, and combination approaches are being explored (45-
48). Due to the limitations of PI3K and AKT inhibitors in clinical studies, novel isoform-specific 
inhibitors, as well as inhibitor combinations, are being explored for clinical efficacy and safety.  
Some of the lack of efficacy of PI3K-AKT and MEK-ERK pathway inhibitors that has been 
observed in clinical trials can be attributed to compensation. For example, MEK inhibitors block 
MEK-ERK signaling, but also promote PI3K-AKT pathway activation through RTK activation 
(49,50). This compensation in pro-survival signaling enables cancer cells and tumors to develop 
resistance to kinase inhibitors. Due to the disappointing efficacy of PI3K and MEK inhibitors as 
monotherapies, combination therapies with PI3K and MEK inhibitors have been explored in 
several clinical trials (51). In fact, approximately two-thirds of PI3K/AKT/mTOR inhibitor trials are 
testing combination approaches, including combinations with chemotherapy, as well as with 
additional kinase inhibitors (i.e. MEK inhibitors) (45). Although combined inhibition of both PI3K-
AKT and MEK-ERK pathways improves efficacy and addresses pathway compensation 
challenges, several dual inhibitor treatments have failed due to significantly higher toxicities than 
monotherapies. (45,52). For example, drug-related toxicities were observed in 53.9% of patients 
when treated with combination of a MEK and a PI3K inhibitor (including transaminase elevations, 
skin rash, and mucositis), compared to only 18.1% in patients receiving monotherapy (45,51). 
Therefore, despite high expectations, combined inhibition of PI3K-AKT and RAS-RAF-MEK-ERK 
has not yet proven to be a viable therapeutic option. Nonetheless, simultanteous inhibition of both 
pathways remains an intriguing strategy to treat cancer. Researchers in this field continue to 
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explore alternative inhibitors, inhibitor combinations, and novel targets to safely and effectively 
inhibit these pathways for therapeutic benefit. 
 
1.1.4 Oncogene and non-oncogene addiction 
Many cancers in which PI3K-AKT and RAS-RAF-MEK-ERK pathways are activated may 
become entirely dependent on these pathways for cell survival and proliferation. The terms 
“oncogene addiction” and “tumor suppressor gene hypersensitivity” describe this dependency of 
cancer cells on particular genetic mutations or activation of oncogenic pathways to maintain the 
malignant phenotype (4,53). This addiction to a particular gene/protein provides a promising 
strategy for cancer treatment, as it suggests that targeted inhibition of a specific oncogene may 
be sufficient to impair cancer cell proliferation and induce cell death. Oncogene addiction results 
in a critical weakness that can be exploited to improve cancer therapy (53). For example, HER2-
positive breast cancer is a breast cancer subtype driven by amplification of the RTK HER2, 
making it attractive for oncogene-targeted therapy. In 1998, the FDA approved trastuzumab (trade 
name Herceptin, Genentech), a monoclonal antibody targeted to the HER2 receptor, for the 
treatment of HER2+ breast cancer. Trastuzumab in combination with chemotherapy significantly 
reduces tumor size and improves overall patient survival compared to chemotherapy alone (54-
56). Thus, targeting a specific oncogene is an effective and clinically-relevant method to treat 
cancer. Additional oncogenes and targeted oncogene inhibitors are being researched and 
developed as targeted cancer therapeutics. 
In addition to identifying cancer targets via oncogene addiction, an emerging source of 
potential cancer therapy targets may be found via the study of non-oncogene addiction. The 
reliance of cancer cells on oncogenes is well-studied and continues to guide the discovery of 
therapeutic targets (57). Non-oncogene addiction, the dependence of a cancer cell on a gene that 
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is not mutated and unable to induce transformation, has begun to yield additional targeted 
treatment options (58,59). A key characteristic of non-oncogene addiction is the differential 
response in cancer versus normal cells. Cancer cells may become particularly reliant on, or 
addicted to, a non-oncogene to support proliferation and survival, whereas normal cells may 
tolerate loss of the same gene. For example, BRCA2-mutant cancers have a defect in double-
strand DNA break repair and consequently are particularly sensitive to DNA damage inducing 
agents (e.g. cisplatin) (60,61). Interestingly, BRCA2 mutant cancer cells are also heavily reliant 
on single-strand DNA repair mechanisms. Inhibition of Poly-ADP-ribose polymerase (PARP1), a 
DNA single strand repair enzyme, has emerged as a viable treatment option in BRCA2-mutant 
cancers (62). PARP1 is not an oncogene, PARP1-/- mice are viable (63), and in the absence of 
genotoxic stress, PARP1 is not required for normal cell survival (64,65). Therefore, the 
dependence of BRCA2 mutant tumors on PARP1-mediated DNA repair is an example of non-
oncogene addiction. PARP1 inhibitors are lethal in BRCA2 mutant cancer cells (62), and have 
been developed and successfully utilized in the clinic (66,67). Olaparib (Lynparza) received FDA 
approval in 2014 for patients with advanced ovarian cancer bearing BRCA mutations, and 
ongoing clinical trials are exploring the benefit of olaparib in BRCA-mutant breast cancer. These 
results confirm the clinical relevance of targeting non-oncogene addiction for therapeutic benefit. 
New genes and proteins that function via oncogene and non-oncogene addiction to 
promote cancer cell survival and proliferation are being characterized. Identification of new targets 
leads to development of improved therapeutics against these novel targets, resulting in better 
outcomes for patients. There is a significant unmet need to identify novel therapeutic targets in 
TNBC and other cancers driven by PI3K-AKT and RAS-RAF-MEK-ERK signaling. This 
dissertation presents compelling evidence for CIB1 as a novel therapeutic target in TNBC. 
 
1.2 CIB1 Introduction 
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CIB1 was discovered in 1997 as a binding partner of the integrin αIIb cytoplasmic tail (68). 
Over the past 18 years, CIB1 structure and function have been explored in cardiovascular 
disease, cancer, and other diseases. Here I will introduce CIB1 by reviewing CIB1 structure, 
binding partners, cell biology, and relevant diseases. 
1.2.1 CIB1 structure 
CIB1 is a 191 amino acid (22kDa) calcium-binding protein with an N-terminal 
myristoylation site (68-70). The structure of CIB1 was determined by multiple studies, utilizing 
techniques including NMR (71-74), circular dichroism (69), and X-ray crystallography (75,76). The 
current consensus CIB1 structure is primarily influenced by the crystal structure solved by Gentry 
et al (75), and NMR studies performed by Hans Vogel and colleagues (71). CIB1 is composed of 
10 α-helices including 4 EF-hands, helix-loop-helix structures capable of divalent cation binding, 
which form the core structure of CIB1 (75). Two of these EF-hand domains bind divalent cation. 
Calcium binds tightly to EF-III (1.9 µM) and EF-IV (0.5 µM) (71,75). Mg2+ binds EF-III as well, but 
with lower affinity than Ca2+. Two additional auxiliary Ca2+-binding sites exist on the surface of 
the N-terminal domain and contribute to CIB1 folding. The N-terminal and C-terminal α-helices do 
not participate in the EF-hand structure. The C-terminal α-helix (H10) of CIB1 lays in a 
hydrophobic binding pocket and is proposed to undergo displacement to enable CIB1 interaction 
with integrin αIIb and other binding partners (71,72).  
The structure of CIB1 changes when bound by different divalent cations. For example, 
Mg2+-bound CIB1 is more flexible in the C-terminus than Ca2+-bound CIB1 (71). These structural 
differences may suggest that CIB1 undergoes conformational changes in response to cellular 
divalent cation availability, as has been shown for several CIB1 homologs (71,77). For example, 
CIB1 has been proposed to function as a Ca2+/myristoyl switch protein (78-80). Further studies 
are required to explore whether cation-dependent conformational changes are relevant to CIB1 
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function. In summary, CIB1 is a small, divalent cation binding protein with a hydrophobic binding 
pocket capable of interacting with multiple binding partners. 
 
1.2.2 CIB1 Binding partners 
CIB1 was discovered as a binding partner of the integrin αIIb cytoplasmic tail, and has 
since been shown to bind many other proteins. CIB1 reportedly binds to at least 41 partners, 
making it a promiscuous and functionally diverse protein (see Table 1-2). Binding partners include 
nuclear, cytoplasmic, and transmembrane proteins (see Figure 1-3). It has been proposed that 
CIB1 is diffusely expressed throughout the cytoplasm and nucleus in normal resting cells, but that 
CIB1 can localize to a particular subcellular area or binding partner upon cellular activation or 
stimulation, such as fluctuations in intracellular Ca2+ concentration (70,78,79,81-85). Further 
work is necessary to fully characterize CIB1 interactions, including cell type specificity, and 
responses to signals and stimuli.  
The interaction of CIB1 with several serine/threonine kinases, PAK1 and PDK1, as well 
as the aforementioned interaction between CIB1 and integrin cytoplasmic tails, are of particular 
interest to this discussion. CIB1-integrin binding will be introduced below, and discussed in detail 
in Chapter 3.  
CIB1-dependent activation of PAK1 (p21 protein(Cdc42/Rac)-activated kinase 1) has 
important implications in cell migration and in pro-survival and pro-proliferation signaling (86). 
CIB1 binds to two sites within the N-terminus of PAK1 and induces PAK1 autophosphorylation, 
and this stimulation of PAK1 activity occurs independent of known PAK1 activators, the small 
GTPases Cdc42 and Rac (86). CIB1-dependent activation of PAK1 may have several 
consequences, including regulation of cell migration (see Section 1.2.4), and MEK-ERK and AKT 
signaling. PAK1 binds and phosphorylates both RAF and MEK, thereby promoting RAS-RAF-
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MEK-ERK signaling (87-91). Interestingly, PAK1 may also facilitate MEK-ERK pathway activation 
independent of its kinase activity by serving as a scaffold to facilitate RAF-MEK binding and 
activation (92). This scaffolding function was previously observed in PI3K-PDK1-AKT signaling, 
where PAK1 functions as a scaffold between PDK1 and AKT to facilitate AKT Threonine (Thr) 
308 phosphorylation (93-95). It is probable that CIB1 regulates AKT and ERK signaling via its 
interaction with PAK1 (96). 
CIB1 also binds and activates PDK1 (3-phophoinositide-dependent protein kinase 1), the 
enzyme that links PI3K and AKT signaling (97). PI3K generates PIP3, and PIP3 binding to PDK1 
is necessary for PDK1 activity. Therefore, localization of PDK1 to the cell membrane is a 
prerequisite for PDK1 activation of its substrates, including phosphorylation of AKT at Thr 308 
(98-100). Zhao et al discovered CIB1 as a PDK1 binding partner, and proposed that CIB1 shuttles 
PDK1 to the cell membrane, thereby facilitating PDK1-AKT interaction and AKT phosphorylation 
(97). Importantly, CIB1-PDK1 binding was demonstrated to be important for cancer cell survival 
and inhibition of stress-induced apoptosis (97).  
Taken together, these studies suggest that CIB1 binding to PAK1 and PDK1 is essential 
to promote the MEK-ERK and PI3K-AKT signaling pathways, as well as cell survival and 
proliferation.  
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Table 1-2. Table of CIB1 binding partners. A comprehensive list of CIB1 binding partners 
reported in the literature, including techniques used to detect the interaction, the cellular location 
of the interacting protein, and the role of CIB1 binding (e.g. activation).  
CIB1 binding partner 
 
Method to Determine Interaction 
 
Location of 
Interaction 
 
CIB1 effect 
(↑) Activates 
(↓) Inhibits 
(−) Interacts/ 
Unknown 
 
AID Y2H (101), In Vitro Pulldown (101), Co-IP (101) Nucleus − 
DNA-PKcs Y2H (102), In Vitro Pulldown (102,103), Co-IP (104) Nucleus ↑ 
EDD Y2H (105), In Vitro Pulldown (105), Co-IP (105) Nucleus − 
hTERT Y2H (104), Co-IP (104) Nucleus ↑ 
PAX3 Y2H (106), In Vitro Pulldown (106) Nucleus ↓ 
TRF2 Y2H (103), In Vitro Pulldown (103) Nucleus ↑ 
InsP(3)R In Vitro Pullodwn (107), Co-IP (85) ER Membrane ↓ 
Presenilin-2 Y2H (108), Affinity Chromatography (108), Co-IP (108), In 
vitro Pulldown (80) 
ER Membrane ↑ 
G1P3 Y2H (109), In Vitro Pulldown (109), Co-IP (109) Mitochondria − 
ASK1 Y2H (84), In Vitro Pulldown (84), Co-IP (84,85) Cytoplasm ↓ 
Calcineurin B Y2H (110), In Vitro Pulldown (110), Co-IP (110) Cytoplasm ↑ 
Caspase-2S Y2H (111), In Vitro Pulldown (111), Co-IP (111) Cytoplasm − 
FAK Co-IP (112) Cytoplasm ↑ 
FNK (PLK3) Y2H (113), ELISA (113,114), Co-IP (114,115) Cytoplasm ↓ 
LMO3 Y2H (116), Co-IP (116) Cytoplasm − 
Myo1c Co-IP (117), In Vitro Pulldown (117) Cytoplasm − 
NBR1 Y2H (118) Cytoplasm − 
PAK1 Co-IP (86), ELISA (86), SPOT peptide assay (86) Cytoplasm ↑ 
PDK1 Co-IP (97) Cytoplasm ↑ 
Rac3 Y2H (119), Co-IP (119) Cytoplasm − 
SCG10 (Stathmin 2) Y2H (120), In Vitro Pulldown (120) Cytoplasm ↓ 
SNK (PLK2) Y2H (113), ELISA (113), Co-IP (121) Cytoplasm ↓ 
Sphingosine Kinase 1 Y2H (78), In Vitro Pulldown (78), Co-IP (78) Cytoplasm ↑ 
Src Co-IP (122) Cytoplasm − 
WASP Y2H (123), SPR (123), Co-IP (123) Cytoplasm − 
Bcl-2 Co-IP (109) Plasma Membrane − 
EphrinA2 Co-IP (82) Plasma Membrane ↑ 
Integrin αIIb Y2H (68), Co-IP (81,83), In Vitro Pulldown (68), ELISA 
(124), ITC (70,124), Intrinsic Tryptophan Fluorescence 
(69), NMR (74) 
Plasma Membrane ↑(83) 
↓(81) 
Integrin αV/α5 Co-IP (124), ELISA (124), ITC (124) Plasma Membrane − 
Integrin α2/α3/α4/αM/αL ELISA (124), ITC (124) Plasma Membrane − 
Integrin α11 Y2H (125), Co-IP (125) Plasma Membrane − 
L-type Calcium Channel Co-IP (126) Plasma Membrane − 
NCX1 Co-IP (126) Plasma Membrane − 
Tas1r2 Y2H (79), Co-IP (79) Plasma Membrane ↓ 
Factor VIII Y2H (127), Co-IP (127) Extracellular − 
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Figure 1-3. Network of CIB1 binding partners. CIB1 (blue) interacts with numerous binding 
partners in the cytoplasm and nucleus. CIB1 often inhibits (red) or enhances (green) a protein’s 
activity, but in some cases the effect of CIB1 binding is unresolved (gray).  
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1.2.3 CIB1 in integrin αIIbβ3 signaling and function 
Following identification of CIB1 as a binding partner for the platelet-specific integrin αIIb 
cytoplasmic tail, early studies from our lab and others focused on understanding the molecular 
and cellular consequences of this interaction. Platelets are anucleate circulating blood cells that 
become “activated” and contribute to thrombus/clot formation in response to vascular injury. As 
the major adhesion receptor on platelets and megakaryocytes (platelet precursor cells), integrin 
αIIbβ3 plays a critical role in the process of platelet-platelet adhesion (aggregation) and 
spreading.  It was hypothesized that CIB1 may play an important role in platelet function by either 
regulating αIIbβ3 activation (inside-out signaling) or αIIbβ3 ligand binding and downstream 
signaling (outside-in signaling) (see Figure 1-4). Because platelets are not amenable to direct 
genetic manipulation, many of the early studies exploring CIB1 function utilized primary 
megakaryocytes and megakaryocyte-like cell lines to understand how CIB1 may regulate αIIbβ3 
outside-in and/or inside-out signaling events. 
Yuan, et al explored the role of CIB1 in αIIbβ3 inside-out signaling, and reported that 
overexpression of CIB1 in megakaryocytes completely inhibits agonist-induced fibrinogen 
binding, while overexpression of a CIB1 mutant that does not bind to the αIIb tail fails to suppress 
αIIbβ3 activation (81).  In addition, RNAi depletion of CIB1 enhances agonist-induced αIIbβ3 
activation, indicating that CIB1 is a negative regulator of αIIbβ3 activation (81). Taken together, 
the data from this study suggest that CIB1 is an inhibitor of integrin αIIbβ3 inside-out signaling.  
Alternatively, some evidence supports a role for CIB1 in integrin αIIbβ3-dependent 
outside-in signaling. Several studies show that CIB1 promotes platelet and megakaryocyte 
adhesion to fibrinogen, potentially by stimulating FAK activity (123,128). Furthermore, multiple 
pieces of evidence suggest that CIB1 preferentially binds to activated integrin αIIbβ3 compared 
to resting αIIbβ3 (81,129). In addition to the studies exploring the role of CIB1 in platelets and 
megakaryocytes, CIB1-dependent regulation of integrin αIIb has been investigated in 
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complementary studies in Chinese Hamster Ovary (CHO) cells overexpressing integrin αIIbβ3. 
CIB1 overexpression in these cells resulted in increased cell spreading and cell migration on 
fibrinogen, reportedly through the interaction between CIB1 with Rac3 (119,122). Cumulatively, 
these studies suggest that CIB1 may promote integrin αIIbβ3 dependent outside-in signaling.  
We and others used CIB1 knockout (CIB1-/-) mice to study the role of CIB1 in platelet 
function, with somewhat differing results from different groups. Naik, et al reported that CIB1-/- 
mice have impaired hemostasis (extended tail bleeding time). Because they found that CIB1-/- 
platelets are also defective in spreading on fibrinogen (the ligand for αIIbβ3) compared to WT 
platelets (130), and that blocking CIB1 with anti-CIB1 antibody decreased platelet spreading (83), 
they concluded that CIB1 is required for outside-in signaling. However, Denofrio, et al found no 
defects in CIB1-/- mouse hemostasis or platelet spreading (131). While much is known about the 
molecular interaction between CIB1 and integrin αIIb, further studies are required to elucidate the 
specific role of CIB1 in inside-out versus outside-in signaling, and to definitively determine 
whether CIB1 is necessary for hemostasis regulation. 
Although CIB1 was originally discovered as a binding partner of the αIIb cytoplasmic 
domain, recent evidence published by Freeman, et al indicates that CIB1 may bind to and regulate 
all integrins via interaction with multiple α-integrin tails. (124) Because CIB1 binds many integrins, 
and is expressed in many tissue types, it is plausible that CIB1 may be a broad regulator of integrin 
function, including integrin-dependent adhesion and migration in many cell types 
(108,111,118,124,132).  
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Figure 1-4. Integrin inside-out and outside-in signaling and potential roles of CIB1 A) 
Integrin αβ heterodimer in resting (bent) conformation, or inactive low affinity state. B) Agonist 
induced inside-out integrin activation. An agonist binds to a receptor on the cell surface. A 
cascade of intracellular signaling events is triggered, culminating in binding of talin and other 
activating factors to the β-integrin cytoplasmic tail, inducing a conformational shift and integrin 
activation that allow high-affinity ligand binding. It is unclear whether CIB1-integrin binding affects 
inside-out integrin signaling. C) Integrin outside-in signaling. Ligand binding to integrin αβ 
heterodimer induces transmission of signals into the cell, including activation of pathways known 
to be regulated by CIB1. The role of CIB1-integrin binding on outside-in signaling is also unknown. 
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1.2.4 CIB1 in cell migration 
The role of CIB1 in cell migration has been explored in multiple contexts, and an interesting 
dichotomy has emerged with some studies concluding that CIB1 inhibits cell migration, and 
contradictory reports suggesting that CIB1 promotes cell migration. Several studies concluded 
that CIB1 expression resulted in increased cell migration on fibronectin in CHO, T47D, HUVEC, 
primary mouse endothelial cells, and megakaryocytes (122,128,133,134). One proposed 
mechanism through which CIB1 could promote cell migration is through activation of kinases ERK 
and PI3K (122). In contrast to these reports, Leisner, et al published that CIB1 inhibits cell 
migration on fibronectin in fibroblast cells via interaction with PAK1. CIB1 binds to PAK1 via the 
NH2-terminal autoinhibitory domain, thereby activating PAK1 and stimulating PAK1-dependent 
LIMK/cofilin signaling resulting in decreased actin polymerization, and consequently decreased 
migration (135). Although multiple studies have observed CIB1-dependent effects on cell 
migration, different studies have reported different outcomes on cell migration. It is possible that 
these discrepancies are due to varying cell types and/or fibronectin concentrations used. 
Nonetheless, these studies indicate that CIB1 plays an important role in regulating cell migration 
via activation of cellular signaling pathways. 
 
1.2.5 CIB1 in calcium signaling 
Calcium has long been shown to be relevant to CIB1 function. Numerous publications 
indicate that intracellular Ca2+ and Mg2+ concentrations may affect the interactions between 
CIB1 and many of its binding partners (68,70,78,79,84,107,120,124). As discussed above (see 
Section 1.2.1) divalent cation binding alters the CIB1 structure and facilitates its molecular binding 
to the integrin αIIb cytoplasmic tail and presumably other binding partners (70,74,136). The 
binding affinity between CIB1 and integrin αIIb CT is significantly enhanced in the presence of 
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either Ca2+ or Mg2+. Although cation-dependent structural differences in CIB1 allude to 
functional consequences such as altered ligand binding, no significant difference in CIB1 binding 
to αIIb CT has been observed between Ca2+-CIB1 and Mg2+-CIB1 (70,74). 
Several studies have explored how CIB1 regulates Ca2+ signaling, as well as how 
intracellular Ca2+ concentrations affect CIB1 function.  Interaction of CIB1 with the inositol 1,4,5 
triphosphate receptor (InsP3R) Ca2+ release channel was found to inhibit Ca2+ release from the 
endoplasmic reticulum (79). In separate studies, ASK1 was shown to bind competitively to CIB1 
and decrease CIB1-InsP3R binding, resulting in increased Ca2+ release, and ROS-induced cell 
death (85). Interestingly, increased Ca2+ decreases CIB1-ASK1 binding, suggesting a potential 
feedback mechanism by which CIB1 may regulate, and be regulated by, intracellular Ca2+ 
release (84). This interplay between CIB1 and intracellular Ca2+ has potentially significant 
functional consequences. CIB1 binding to ASK1 inhibits ASK1 kinase activity, interferes with 
ASK1 binding to additional binding partners (e.g. TRAF2), and mitigates ROS-induced cell death 
in SH-SY5Y neuroblastoma cells (84). These results indicate an important role for CIB1 in the 
relationship between ASK1 and InsP3R in Ca2+-dependent signaling and maintenance of cell 
viability. Further studies are necessary to better understand the cellular consequences of Ca2+ 
concentration on CIB1 interactions and function. Although many details remain unknown, these 
results suggest that changes in intracellular divalent cation concentrations and binding to CIB1 
are likely to influence CIB1 function. 
 
1.2.6 CIB1 myristoylation 
CIB1 is N-terminally myristoylated, a modification that may have important implications in 
CIB1 cellular localization and signaling (78-80,110). Myristoylation, the post-translational addition 
of a 14-carbon saturated fatty acid myristoyl moiety to the N-terminal glycine of a target protein, 
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is an essential cellular process with implications in cancer and infectious diseases (137). 
Interfering with CIB1 myristoylation via mutations or protein fusions at the CIB1 N-terminus 
interferes with the cellular functions of CIB1 (78,79,97,108,110). Several publications concluded 
that CIB1 myristoylation is important to direct CIB1 to the membrane (79) and to facilitate shuttling 
of CIB1 binding partners, such as sphingosine kinase 1 (SK1) (78) and calcineurin B (CnB) (110), 
to the membrane. Some myristoylated proteins such as recoverin and visinin-like protein 1 (VILIP-
1) behave as Ca2+/myristoyl switches, where the protein undergoes a conformational shift upon 
binding to Ca2+, leading to the exposure of the buried N-terminal myristoyl moiety to the 
intracellular environment (138,139). While no structural evidence exists that CIB1 behaves in such 
a manner, Jarman, et al reported that CIB1 functions as a Ca2+/myristoyl switch and shuttles SK1 
to the cell membrane in an agonist- and Ca2+-dependent manner.  CIB1 interacts with the 
calmodulin binding site of SK1 and is required for SK1-dependent generation of the anti-apoptotic 
signaling molecule sphingosine-1-phosphate to promote SK1-dependent cell survival (78). The 
authors proposed an interesting model, whereby cytoplasmic CIB1 binds to Mg2+ under basal 
conditions which prevents the interaction of CIB1 and SK1. Upon increased intracellular Ca2+, 
the myristoyl group is released, enabling CIB1 to shuttle various binding partners to the 
membrane. Despite some controversy over whether CIB1 functions as a Ca2+/myristoyl switch 
per se (79,80), these findings suggest a mechanism by which CIB1 can regulate binding partner 
function at the cell membrane. Further studies are necessary to determine whether CIB1 in fact 
functions as a Ca2+/myristoyl switch and to further define how CIB1 myristoylation affects cell 
biology and disease. 
1.2.7 CIB1 in cell survival and proliferation 
A growing body of evidence supports an important role for CIB1 in promoting cancer cell 
survival and proliferation. Cells vigilantly regulate their survival and proliferation via several 
signaling pathways. Uncontrolled cell survival and proliferation can result in tumor development 
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and cancer, as well as other diseases. The first reported observation of a CIB1-dependent effect 
on cell proliferation came in 2006, when Yuan, et al reported that MEFs derived from CIB1-/- 
embryos proliferated at a slower rate than WT MEFs (140). In subsequent studies, endothelial 
cells derived from CIB1-/- mice also showed reduced proliferation rates compared to WT controls, 
providing additional evidence for a compelling link between CIB1 and proliferation (133). Recently, 
several independent reports have suggested that CIB1 promotes cancer cell proliferation and 
survival by regulating oncogenic signaling pathways (78,84,85,96,141,142). Leisner et al. 
explored one potential mechanism through which CIB1 promotes proliferation and survival and 
found that CIB1 promotes the activation of ERK and AKT, essential components of two pro-
proliferation and pro-survival signaling pathways frequently activated in breast cancer (96,143). 
The Ras-Raf-MEK-ERK and PI3K-AKT pathways are frequently activated in cancer cells (144). 
RNAi knockdown of CIB1 in MDA-MB-468 breast cancer cells and SK-N-SH neuroblastoma cells 
led to decreased ERK and AKT phosphorylation and induced translocation of GAPDH to the 
nucleus. Nuclear GAPDH either induces or correlates with several additional events, including the 
activation of histone variant γH2AX and checkpoint protein CHK1. These events are markers of, 
or directly lead to, DNA damage, dysregulation of cell cycle checkpoints, and induction of non-
apoptotic cell death (96). It is likely that CIB1 promotes ERK and AKT activation via its interactions 
with PAK1 and PDK1 (see Figure 1-5). Additional studies provide evidence that CIB1 promotes 
ERK and AKT activation and signaling, supporting the mechanism proposed by Leisner, et al 
(82,122,135).  
A growing body of evidence indicates that CIB1 depletion may lead to decreased cancer 
cell proliferation and survival. Further work is necessary to better understand the primary and 
secondary pathways involved in this important cellular phenotype, and to understand how CIB1 
may regulate cell survival and proliferation in various diseases, including cancer. 
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Figure 1-5. Role of CIB1 in activation of AKT and ERK signaling pathways Extracellular RTK 
ligands (e.g. EGF) bind to RTK (receptor tyrosine kinase, e.g. EGFR) leading to RTK activation. 
Activated RTK, either directly or indirectly, activates PI3K and RAS, initiating a cascade of events 
that promote cell survival, cell proliferation, and gene expression. CIB1 binds to and activates 
PAK1, which activates MEK-ERK signaling and facilitates activation AKT. CIB1 also binds and 
activates PDK1, a direct upstream activator of AKT. Through its interaction with PAK1 and PDK1, 
CIB1 promotes activation of MEK-ERK and PI3K-AKT signaling, resulting in cell survival, cell 
proliferation, and gene expression. 
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1.2.8 CIB1 in Cancer 
Cancer is a heterogeneous disease caused by oncogene activation and/or tumor 
suppressor inactivation. Cancer cells become reliant on cell signaling pathways to promote cell 
survival and proliferation (53). For example, many basal-like breast tumors exhibit activated ERK 
and AKT signaling pathways (28,145,146). In addition, cancer cells may become reliant on non-
oncogenes via non-oncogene addiction, a description of non-mutated non-overexpressed 
genes/proteins that are essential for cancer cell survival but dispensable for normal cells (58).  
In addition to internal factors driving tumor cell survival and proliferation, growing tumors 
depend on a steady blood supply to provide nutrients and oxygen (147). As tumors grow, they 
stimulate new blood vessel growth, a process termed tumor-induced angiogenesis. Angiogenesis 
inhibitors have been researched and used clinically to prevent tumor growth and induce tumor 
regression (e.g. bevacizumab) (148,149). The role of CIB1 in tumor-induced angiogenesis has 
been explored using molecular, cellular, and in vivo models. 
CIB1 is important in two critical aspects of tumor growth: cell survival and tumor-induced 
angiogenesis. As described above (Section 1.2.7), numerous publications have reported that 
CIB1 depletion from cancer cell lines results in a decrease in proliferation and/or an increase in 
cell death (78,84,85,96,141,142). Furthermore, high CIB1 expression has been implicated in 
cancer progression and incidence. CIB1 expression was found to be higher in breast tumor 
tissues relative to patient-matched control tissues (114). In an examination of hepatocellular 
carcinoma tissues, CIB1 expression was found to be elevated in the tumor margin and tumor 
center compared to non-tumor tissue, and high CIB1 expression was more prevalent in late stage 
compared to early stage tumors (141). In addition to its role in cancer cells, CIB1 expression is 
also essential for endothelial cell function and tumor-induced angiogenesis. Zayed et al 
demonstrated that CIB1 depletion impaired endothelial cell migration (133). Furthermore, CIB1-/- 
mice did not support tumor growth; murine tumors grafted into CIB1-/- mice were necrotic due to 
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a reduced blood supply (150). These data suggest that CIB1 is critical for both tumor cell survival, 
as well as tumor-induced angiogenesis. CIB1 should be further interrogated in specific cancer 
subtypes to determine whether it might be a novel therapeutic target. 
 
The significant unmet need for improved therapeutic options for TNBC, and the research 
demonstrating a role for CIB1 in cancer cell survival and proliferation, served as the stimulus for 
the research questions explored in Chapter 2 of this dissertation. Here I present compelling 
evidence that CIB1 is essential for cell survival and tumor growth in one cancer sub-type, TNBC. 
The growing body of literature, in combination with the data presented herein, supports a potential 
role for CIB1 in additional cancers as well. Taken together, these data validate CIB1 as a novel 
therapeutic target for the treatment of cancer, and warrant further investigation in TNBC and other 
cancer subtypes. 
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CHAPTER 2: CIB1 DEPLETION IMPAIRS CELL SURVIVAL AND TUMOR GROWTH IN 
TRIPLE NEGATIVE BREAST CANCER 
 
2.1 Introduction 
Breast cancer is diagnosed in over 230,000 people each year in the United States (10). 
Approximately 16% of all new breast cancer diagnoses are triple negative breast cancer (TNBC), 
a subtype of breast cancer that lacks expression of estrogen receptor, progesterone receptor, 
and human epidermal growth factor receptor 2 (11). Many breast cancer therapies target one of 
these three receptors and are therefore ineffective for the treatment of TNBC.  
In breast cancer, and other cancers, cell survival and cell proliferation are driven by 
oncogenic signaling pathways. A majority of TNBC cases are basal-like, and typically exhibit 
constitutively activated RAF-MEK-ERK and PI3K-AKT signaling pathways (11,151).  Dual 
inhibition of both ERK and AKT signaling pathways has been identified as a promising approach 
to treat TNBC (151,152). However, preclinical and clinical studies have suggested that combined 
inhibition of both PI3K and MEK may improve efficacy at the expense of increased toxicity 
(17,45,51). New targeted therapies with enhanced efficacy and safety are necessary to improve 
patient outcomes (14,153). 
CIB1 is a small intracellular protein that regulates kinase activity and integrin biology 
(78,81,84,86,96,113,124), and has an emerging role in cancer cell survival and proliferation via 
regulation of oncogenic signaling pathways (78,84,85,96,141). For example, CIB1 promotes AKT 
and ERK activation (82,96), and may regulate these pathways via interaction with the 
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serine/threonine kinase PAK1 (86,122). We recently showed that CIB1 depletion in two cancer 
cell lines (SK-N-SH neuroblastoma and MDA-MB-468 TNBC) disrupted both AKT and ERK 
signaling, resulting in the induction of a DNA damage response and a unique mechanism of non-
apoptotic cell death (96).  
Because of our initial observation that CIB1 is essential for MDA-MB-468 TNBC growth 
and survival in vitro, we hypothesized that CIB1 may have a broader role in TNBC and in tumor 
growth in vivo. Here we present evidence that CIB1 is necessary for proliferation and survival in 
TNBC cell lines with elevated AKT activation and/or low PTEN expression. We further 
demonstrate that CIB1 depletion results in dramatic TNBC tumor shrinkage in vivo. To gain further 
insight into the effects of CIB1 depletion, we present RNA sequence (RNAseq) analysis revealing 
that CIB1 depletion induces genetic programs that correlate with decreased proliferation and 
survival, and cell differentiation. We show that high CIB1 expression is not associated with 
susceptibility to CIB1 depletion or with TNBC patient prognosis. Taken together, these findings 
are consistent with the emerging theory of non-oncogene addiction, where a subset of TNBCs 
appear to be reliant on a non-oncogenic protein, CIB1, for cell survival and tumor growth. Our 
results further suggest that CIB1 may be a novel target for TNBC therapy. 
 
2.2 Results 
2.2.1 CIB1 depletion induces cell death in a TNBC cell line panel 
Recent reports have indicated that CIB1 promotes survival and proliferation in several 
cancer cell lines, including one TNBC cell line (84,85,96,141). We therefore screened a panel of 
eleven TNBC cell lines for their susceptibility to shRNA-mediated CIB1 depletion. We found that 
CIB1 depletion significantly increased cell death in eight of eleven (73%) cell lines tested (Figure 
2-1A). One cell line that showed only a moderate increase in cell death that was not statistically 
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significant, HCC1143 (Figure 2-1A, P=0.08), did exhibit a significant decrease in proliferation rate 
(Figure 2-2A, P<0.003). Ultimately, we observed some response in either cell viability, cell 
proliferation, or both, in nine out of eleven TNBC cell lines.  
Pharmacological inhibition of both the ERK and AKT signaling pathways, but not either 
pathway alone, induces TNBC cell death (96,154). We previously showed that CIB1 depletion 
impaired both ERK and AKT activation, leading to significant cell death in MDA-MB-468 cells (96).  
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Figure 2-1. CIB1 depletion induces cell death in a panel of TNBC cell lines. A) A panel of 11 
TNBC cell lines were transduced with either control (CTRL) or two separate CIB1 shRNA targeting 
sequences. Results are expressed as the mean percentage of dead cells (i.e. trypan blue positive 
cells) from both adherent and floating cell populations, data represent mean ± SEM from n ≥ 3 
experiments. P-values were calculated using Student’s T-test. **P<0.01; *P<0.05. B) Relative 
protein levels of PTEN, pAKT, AKT, pERK, ERK, CIB1, and Rac (additional loading control) in 
TNBC cell lines treated with CTRL or CIB1 shRNA as in (A). All membranes were processed 
under the same conditions. Blots are representative of three independent experiments. Figure 
used with permission from (155).  
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Therefore, we compared activated (phosphorylated) ERK (pERK) and AKT (pAKT) levels 
in CIB1-depleted versus control cells in the TNBC cell line panel (Figure 2-1B). We first noted that 
CIB1 depletion resulted in decreased pERK and pAKT in most cell lines. Interestingly, we 
observed that CIB1 depletion increased cell death in all eight cell lines that have relatively high 
basal levels of pAKT, and noted that seven out of these eight cell lines also had elevated pERK. 
However, pERK is also elevated in two out three cell lines that did not respond to CIB1 depletion 
and, therefore, ERK phosphorylation status does not appear to be a good predictor of sensitivity 
to CIB1 depletion.  
Because the tumor suppressor PTEN is an upstream inhibitor of AKT activation and 
several of the cell lines from our TNBC panel have PTEN mutations (Table 2-1), we also 
interrogated the PTEN status in each TNBC cell line.  Interestingly, PTEN protein expression was 
absent or reduced in seven of eight cell lines that responded to CIB1 depletion, but was normal 
in all three cell lines that were not sensitive to CIB1 depletion (Figure 2-1B). These results suggest 
that PTEN status may be an additional predictor of responsiveness to CIB1 inhibition. To further 
explore differences between sensitive and insensitive cell lines, we examined gene expression 
microarray data (156) for each cell line in the panel. Using Significance Analysis of Microarrays, 
we identified two genes that were significantly (false discovery rate equal to zero) upregulated in 
cells that are insensitive to CIB1 depletion, NBEA (fold change +5.6) and FUT8 (fold change 
+4.9). As both of these genes are involved in cell differentiation, we compared the average 
Differentiation Score (156,157) of the sensitive and insensitive cell lines and found that cell lines 
that were not sensitive to CIB1 depletion trended toward a more differentiated state compared to 
the cell lines that were sensitive to CIB1 depletion (Figure 2-2). Finally, we observed that CIB1 
expression was variable in the TNBC cell line panel, and that there was no association between 
high CIB1 expression and sensitivity to CIB1 depletion. These results indicate that CIB1 inhibition 
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may be a therapeutic approach to induce TNBC cell death regardless of CIB1 expression levels, 
particularly in cells with high basal levels of pAKT and/or low levels of PTEN. 
To determine whether CIB1 depletion induces cell death in other breast cancer subtypes, 
we measured the effect of CIB1 depletion in three non-TNBC mammary cell lines: ZR-75-1 
(Luminal A subtype); SKBR3 (HER2 overexpressing); and ME16C (non-cancerous mammary 
epithelial cell line). We observed a significant increase in cell death in CIB1-depleted ZR-75-1 
cells (Figure 2-3). Consistent with our observations from the TNBC cell line panel, the ZR-75-1 
cells are PTEN-null, whereas SKBR3 and ME16C are PTEN WT and do not have increased cell 
death upon CIB1 depletion. These data suggest that, in addition to TNBC, CIB1 inhibition may be 
effective in additional PTEN-null breast cancers and other cancers. 
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Figure 2-2. CIB1 depletion reduces cell proliferation in a panel of TNBC cell lines. A) A panel 
of 11 TNBC cells lines were transduced with either control (SCR) or two separate CIB1 shRNA 
targeting sequences (CIB1 shRNA1 or shRNA2). SCR was normalized to 1.0 (dotted line) and 
graph represents relative mean fold change in total cell count ± SEM for each CIB1 shRNA treated 
sample (n ≥ 3). B) Average differentiation score of sensitive and insensitive cell lines from TNBC 
cell line panel. Cell lines sensitive to CIB1 depletion trend toward a lower differentiation score 
than insensitive cell lines (p = .0695). Figure used with permission from (155). 
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Cell Line PTEN mutation PTEN Protein Source 
SUM149 GPM (micro-CNI) Null (35,158)  
BT549 822delG (L295X) Null (35,159)  
MDA-436 GPM (micro-CNI) Null (35)  
Hs578T WT Positive (35)  
SUM159 WT Positive (35,158)  
MDA-468 IVS4+1G4T (A72fsX5) Null (35,159)  
HCC1937 GPM (HD) Null (35,159)  
SUM102 WT Unknown (158,160)  
HCC1143 WT Positive (161,162)  
MDA-231 WT Positive (35)  
MDA-453 919G4A (E307K) Positive (35,159)  
 
Table 2-1. PTEN status in TNBC cell line panel. Known PTEN mutations and the PTEN 
expression status according to published sources. Table used with permission from (155).   
 35 
 
 
 
Figure 2-3. Effect of CIB1 depletion on cell death in non-TNBC cell lines. A) A panel of three 
non-TNBC cell lines were transduced with either control or CIB1 shRNA. Graph represents 
average percent cell death ± SEM for each sample (n = 3). ZR-75-1 had significantly higher cell 
death upon CIB1 depletion. B) Relative levels of pAKT, AKT, pERK, ERK, CIB1, and Rac (loading 
control) in CIB1-depleted and control samples. CIB1 depletion results in reduction in pAKT and 
pERK in ZR-75-1 cells, corresponding to increased cell death. Figure used with permission from 
(155). 
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2.2.2 CIB1 depletion from MDA-MB-468 TNBC cells decreases proliferation and increases cell 
death 
Data presented here and elsewhere demonstrate that CIB1 depletion increased cell death 
of MDA-MB-468 (MDA-468) cells (Figure 2-1) (96), but not in non-cancerous cells (133,163).  
While these data suggest that CIB1 may be a promising target for TNBC therapy, we sought in 
vivo validation. We utilized a doxycycline-inducible shRNA system to regulate CIB1 expression in 
MDA-468 tumor xenografts. MDA-468 cells were engineered to express either CIB1 shRNA 
(MDA-468-CIB1shRNA) or control (scrambled) shRNA (MDA-468-SCRshRNA) in response to the 
antibiotic doxycycline (Dox). MDA-468-CIB1shRNA cells treated with doxycycline showed 
significant depletion of CIB1 by Western blot (Figure 2-4C). Consistent with previous findings (96), 
CIB1 depletion decreased phosphorylation of ERK and AKT and increased phosphorylation of 
the DNA damage marker, γH2AX (Figure 2-4C).  
Because treatment response in the 2D clonogenic survival assay in vitro typically agrees 
with tumor treatment response in vivo (164), we performed a 2D clonogenic assay to measure 
MDA-468-CIB1shRNA and MDA-468-SCRshRNA colony formation in 2D cell culture. CIB1 
depletion in MDA-468 cells (MDA-468-CIB1shRNA+Dox) resulted in a complete loss in the ability 
to form colonies (Figure 2-5A). Importantly, doxycycline treatment of control cells (MDA-468-
SCRshRNA+Dox) had no effect on colony formation ability. We next measured the effect of CIB1 
depletion on MDA-468 cell proliferation and survival in culture. CIB1 depletion resulted in arrested 
proliferation and a ~12-fold increase in cell death (Figure 2-4A). To better quantify the cell death 
induced by CIB1 depletion, we performed flow cytometry to measure phosphatidylserine (PS) cell 
surface expression via Annexin V staining, and cell permeability to 7-AAD. The majority of CIB1 
depleted cells were in either early (Annexin V positive – 22.6%) or late (Annexin V positive and 
7-AAD positive – 37.3%) stages of cell death (Figure 2-4B). Thus, in cell culture, conditional 
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shRNA knockdown of CIB1 recapitulates the effects of CIB1 depletion using conventional shRNA 
knockdown.  
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Figure 2-4. CIB1 depletion decreases TNBC cell proliferation and increases cell death in 
vitro and in vivo. A) CIB1 depletion decreases MDA-468 proliferation and viability. Graphs 
represent mean total cell number ± SEM (Upper panel) and mean percentage of dead cells ± 
SEM (Lower panel) at each time point (n=3). *P<.001; ** P<.01. B) Measurement of cell surface 
phosphatidylserine (Annexin V binding) and cell permeability to 7-AAD. A higher percentage of 
MDA-468-CIB1shRNA+Dox cells were positive for both Annexin V and 7-AAD, indicating a higher 
percentage of dead cells. C) Relative levels of pAKT, AKT, pERK, ERK, CIB1, γH2AX, and Rac 
(loading control) in CIB1-depleted and control samples in vitro from proliferation and survival 
assays (A). MDA-468-CIB1shRNA+Dox exhibit complete depletion of CIB1, decreased pERK and 
pAKT, and increased γH2Ax (C). Figure used with permission from (155).   
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2.2.3 CIB1 is required for MDA-MB-468 xenograft tumor growth 
To test whether CIB1 was necessary for TNBC tumor growth and survival in vivo we used 
a xenograft model and injected MDA-468-CIB1shRNA and MDA-468-SCRshRNA cells 
subcutaneously into the flanks of immunocompromised mice. Once tumors reached a volume of 
approximately 100 mm3, mice were randomized into groups receiving sucrose, or sucrose plus 
doxycycline, and tumor volume was monitored for 5 weeks. We observed a rapid arrest of tumor 
growth followed by a drastic decrease in tumor volume in CIB1-depleted tumors (Figure 2-4B). In 
contrast, control tumors continued to grow steadily throughout the treatment period. After 5 
weeks, CIB1-depleted tumors were not visible compared to control tumors, which were visibly 
bulging from the flanks of the mice. Upon completion of the study, tumors were resected and 
weighed. The average mass of CIB1-depleted tumors was significantly smaller than control 
tumors (Figure 2-5C).  
To better understand how CIB1 depletion affects TNBC tumors, resected xenograft tumors 
were fixed, stained, and analyzed by microscopy. Histological analysis revealed that CIB1-
depleted tumors had relatively few remaining cells and were composed mostly of non-cellular 
tissue (pink), whereas control tumors were composed of densely packed cells (blue) (Figure 2-
5D). Because CIB1 is essential for maintaining double strand break repair in TNBC cells (96,103), 
we asked whether CIB1-depleted TNBC tumors exhibited increased TUNEL staining, which 
detects dead or dying cells by labeling DNA double-strand breaks. Images of TUNEL-stained 
sections revealed that more of the remaining CIB1-depleted cells were TUNEL-positive compared 
to control tumors (Figure 2-6B). Finally, a portion of each tumor was lysed for analysis by Western 
blotting. Consistent with CIB1 depletion in vitro, CIB1-depleted tumors had lower CIB1 
expression, and decreased pERK and pAKT levels compared to control tumors (Figure 2-6A). 
This initial examination of the role of CIB1 in tumor growth in vivo suggests that CIB1 inhibition 
may be an effective therapeutic strategy for the treatment of TNBC tumors. 
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Figure 2-5. CIB1 depletion shrinks TNBC tumors in vivo. MDA-468 cells were engineered to 
stably express doxycycline (Dox)-inducible CIB1 shRNA (MDA-468-CIB1shRNA) or scrambled 
shRNA (MDA-468-SCRshRNA). A) CIB1 depletion in MDA-468 cells results in complete loss of 
cell proliferation and colony formation in a 2D clonogenic assay. Data represent mean ± SEM, n 
= 3.  ** P<0.005, * P<0.01.  B) MDA-468 xenograft studies. Graph represents average tumor 
volume ± SEM. N=8 mice per treatment group. P-values were calculated by Student’s T-test for 
the average final tumor volume ** P< 0.005. C) Representative images show tumors bulging from 
the flanks of control mice, but not CIB1shRNA+Dox mice (upper panel). After 5 weeks, mice were 
sacrificed and resected tumors were imaged (middle panel) and weighed (lower panel). Data 
represent average mass ± SEM (n = 8) ** P<0.005, * P<0.01. D) Representative images of H&E 
stained tumor sections show that CIB1-depleted tumors are less dense than control tumors. Pink 
(eosin) – non-cellular tissue. Blue (hematoxylin) – cell nuclei. Figure used with permission from 
(155).   
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Figure 2-6. CIB1 depletion decreases pERK and pAKT and increases DNA damage in vivo. 
A) Relative levels of pAKT, AKT, pERK, ERK, CIB1, γH2AX, and Rac (loading control) in CIB1-
depleted and control samples in vivo. MDA-468-CIB1shRNA+Dox exhibit complete depletion of 
CIB1, and decreased pERK and pAKT. B) CIB1-depleted tumors have more DNA damage than 
control tumors. Representative TUNEL-stained xenograft tumor sections show that more of cells 
from CIB1-depleted tumors are dead or dying (dark brown punctate dots) compared to control 
tumors. Figure used with permission from (155). 
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2.2.4 PAK1 activation partially rescues cells from CIB1 depletion 
CIB1 binds and activates PAK1 (86), and we previously hypothesized that the role of CIB1 
in promoting AKT and ERK activation was mediated by PAK1 (96). To test whether PAK1 
activation could rescue cells from CIB1 depletion-induced cell death, we overexpressed 
constitutively active PAK1 (caPAK1) in MDA-468 cells, then knocked down CIB1 and measured 
cell death. We observed that expression of caPAK1 resulted in a partial rescue of cell death in 
response to CIB1 depletion (Figure 2-7). These data suggest that CIB1-PAK1 binding is not 
exclusively responsible for CIB1-dependent cell survival, and that additional factors may 
contribute to CIB1 signaling to promote survival and proliferation. 
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Figure 2-7. Expression of constitutively active PAK1 partially rescues CIB1 depletion-
induced cell death. A) caPAK1 was overexpressed in MDA-468 cells, followed by treatment with 
either control or CIB1 shRNA. caPAK1 expression partially rescued cells from CIB1-depletion 
induced cell death. Graph represents average percent dead cells ± SEM (n = 2). B) Relative levels 
of PAK1, pAKT, AKT, pERK, ERK, CIB1, and GAPDH (loading control) in control or CIB1 shRNA 
treated cells ± caPAK1 overexpression. Figure used with permission from (155).   
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2.2.5 CIB1 depletion induces genetic programs that reduce proliferation and survival 
Because CIB1 depletion induces cell death by a unique, non-apoptotic mechanism that is 
only partially understood (96), we measured global changes in gene expression by RNAseq 
analysis to gain additional mechanistic insight into the effects of CIB1 depletion. Total mRNA was 
isolated from viable control and CIB1-depleted MDA-468 cells <96 hours after shRNA induction, 
since extended CIB1 depletion induces nearly complete MDA-468 cell death (Figure 2-4A). We 
identified 812 genes that were significantly upregulated (Appendix A) or downregulated (Appendix 
B) upon CIB1 depletion. Because sensitivity to CIB1 depletion in the TNBC cell line panel was 
associated with cellular differentiation, as measured with the Differentiation Score (see Figure 2-
2), we asked whether CIB1 depletion-induced changes in gene expression were associated with 
genes involved in cell differentiation. We compared the CIB1 depletion-induced differentially 
expressed genes (CIB1 KD gene signature) to 10,508 known gene signatures (from public 
databases such as GSEA and also from manual curation). Interestingly, several gene signatures 
that had strong Pearson correlation values with the CIB1 KD gene signature were prominent in 
genetic programs that mediate differentiation and cancer stem cell function (see Appendix C). For 
example, we observed an increase in 5 out of 7 genes from a mammary stem cell gene signature 
(165), and an increase in 11 out of 16 genes from an epithelial to mesenchymal transition (EMT) 
gene signature (166) (Figure 7B). We also observed a decrease in 5 out of 6 genes from a breast 
cancer proliferation gene signature (167). These results support previous observations that CIB1 
depletion correlates with decreased cell proliferation, and indicate that CIB1 depletion activates 
genetic programs consistent with mammary stem cells and EMT. Interestingly, we observed 
nearly complete cell death in MDA-468 cells after extended CIB1 depletion (Figure 2-4A), 
suggesting that CIB1-depleted cells do not become stem cells, but rather acquire some stem-like 
characteristics as they are dying. As we described previously, CIB1 depletion in MDA-468 cells 
results in cell death by a unique non-apoptotic mechanism (96). It is possible that the observed 
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differential gene expression is a downstream cellular response to overcome the negative effects 
of CIB1 depletion, rather than a direct effect of loss of CIB1. Further experiments are required to 
follow up on this interesting observation. 
Because CIB1 depletion induces MDA-468 cell death, we next examined the RNAseq data 
for differential expression of genes involved in cell survival and cell death. We identified 99 
differentially expressed genes that were positively associated with increased cell death (several 
of these genes are listed in Figure 2-8C-D). For example, we observed a Log2 fold change of 
+4.1 for the gene DKK3 (Dickkopf-3). DKK3 is a secreted glycoprotein that potently inhibits Wnt 
signaling pathways (168), and has been characterized as a tumor suppressor. Interestingly, DKK3 
expression is suppressed in breast cancer (169). Adenovirus-mediated delivery of the DKK3 gene 
to xenograft tumors resulted in tumor regression and induction of cell death in prostate, testicular, 
and breast cancer models (170-172). Taken together, these results suggest that CIB1 depletion-
mediated upregulation of DKK3 may have therapeutic benefit in killing cancer cells and inducing 
tumor regression, and support the tumor regression data presented herein (See Figures 2-5 and 
2-6).  
CIB1 depletion also resulted in decreased expression of several known cancer drug 
targets, suggesting that inhibiting CIB1 could broadly inhibit multiple targets simultaneously 
(Figure 2-8D). For example, CIB1 depletion led to decreased expression of two isoforms of 
glutathione-s-transferase, an enzyme that protects cells from oxidative stress and is implicated in 
chemotherapy drug resistance, indicating that CIB1 interference may sensitize TNBC cells to 
chemotherapy or other stress-inducing targeted therapies (173). Several naturally occurring 
compounds are known to inhibit glutathione-s-transferases, including quinine, thonningianin A, 
quercetin, cucumin, and coniferyl ferulate (174). Furthermore, glutathione-s-transferase inhibition 
is an effective means to reverse multidrug resistance in pre-clinical studies and has been 
proposed as an adjuvant therapy or chemopreventive treatment (174-177). Tissue factor is 
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another example of a cancer drug target gene downregulated upon CIB1 depletion. Tissue factor 
is normally considered in the context of the coagulation cascade, but has recently been shown to 
promote cancer progression, including breast cancer (178,179). Treatment with tissue factor 
inhibitor ixolaris reduced tumor growth and metastasis in mouse tumor models (180,181). 
Therefore, CIB1 depletion-induced knockdown of tissue factor provides another beneficial effect 
of targeting CIB1 in TNBC. These examples (glutathione-s-transferase and tissue factor) of CIB1 
depletion-induced downregulated genes suggest that inhibition or knockdown of CIB1 may 
simultaneously inhibit multiple cancer drug targets. 
Taken together, these results demonstrate meaningful changes in gene expression 
induced by CIB1 depletion. Further experiments should explore the role of CIB1 in EMT and 
mammary stem cells to better understand how CIB1-dependent gene expression influences these 
genetic programs. Nonetheless, the striking number of genes involved in cell survival and cell 
death that are differentially expressed upon CIB1 depletion demonstrates an important role for 
CIB1 in maintenance of cell viability. We propose that examination of CIB1-dependent 
differentially expressed genes could lead to identification of additional novel drug targets or 
potential combination therapies.  
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Figure 2-8. CIB1 depletion results in differential expression of 812 genes. A) Heat map of 
top 60 genes differentially expressed upon CIB1 depletion (red = upregulated; blue = 
downregulated). B) Overlap of 812 differentially expressed genes with three known breast cancer 
gene signatures (165-167). Five of six genes from a proliferation signature decreased, eleven of 
sixteen genes from an EMT signature increased, and five of seven genes from a mammary stem 
cell signature increased. C-D) Selected upregulated (C) and downregulated (D) genes predicted 
to increase cell death. Several gene products have known inhibitors that have been tested for 
efficacy in cancer. Figure used with permission from (155). 
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2.2.6 CIB1 mRNA expression does not correlate with TNBC prognosis 
Recent reports have suggested that CIB1 expression may have prognostic implications in 
breast cancer (114). Since CIB1 protein levels did not appear to correlate with susceptibility to 
CIB1 depletion in the TNBC cell line panel examined in Fig. 1, we predicted that CIB1 mRNA 
expression might not be prognostic of survival in TNBC patients. We therefore tested the 
association of CIB1 and disease progression in four independent breast cancer gene expression 
datasets (157,182-184). Though some datasets trended towards an association of high CIB1 
expression and faster disease recurrence, Kaplan-Meier survival analyses found no significant 
association (p<0.05) of patient relapse-free survival and CIB1 mRNA level within estrogen 
receptor negative tumors or triple negative tumors in any of the datasets tested (Figure 2-9). 
These results indicate that CIB1 expression levels alone are not a reliable indicator of prognosis 
in TNBC. 
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Figure 2-9. CIB1 expression is not prognostic for TNBC patient survival. A) CIB1 expression 
in a population of human ER-negative tumors does not correlate with probability of relapse-free 
survival by Kaplan-Meyer survival analysis (n=256). Human breast tumor gene expression 
microarray data was obtained from a dataset generated by Harrell et al (182). B) Same as in (A) 
but focusing on subset of TNBC within the ER-negative tumors (n=110). Figure used with 
permission from (155).   
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2.3 Discussion 
TNBC is a breast cancer subtype with generally poor prognosis and no available targeted 
treatment options (14). Two oncogenic pathways, RAF-MEK-ERK and PI3K-AKT, are aberrantly 
active in the majority of TNBC (151). Because CIB1 promotes both of these signaling pathways 
(96), we hypothesized that CIB1 might be essential to TNBC cell survival. The data presented 
here provide evidence that CIB1 depletion impairs cell survival in a majority of TNBC cell lines 
and shrinks TNBC xenograft tumors, suggesting that CIB1 may have a broad role in TNBC 
survival and tumor growth. Furthermore, dependence on CIB1 expression is associated with 
active AKT and/or low PTEN expression. PTEN mutation or deletion is significantly associated 
with incidence of basal-like breast cancer in mice and humans (35,185). These data suggest that 
CIB1 inhibition may be an effective therapeutic option for TNBC patients with PTEN-deficient 
tumors. 
CIB1 depletion impairs ERK and AKT activation in the majority of cell lines, but often does 
not completely eliminate phosphorylation of these two kinases (see Figure 2-4C). This raises the 
question of whether the effects of CIB1 depletion on cell survival and proliferation are due 
exclusively to the decrease in p-ERK and p-AKT, or whether additional mechanisms might be 
contributing to the observed phenotype. The interaction between CIB1 and the kinases SK1 and 
ASK1 (see Table 1-2) provides two potential alternative means by which CIB1 could promote cell 
proliferation and survival, and protect from cell death (78,84,85). CIB1 activates SK1, which 
promotes cell survival by generating sphingosine-1-phosphate, an important anti-apoptotic lipid 
messenger (186-188). In addition, CIB1 inhibits ASK1, thereby preventing ASK1-mediated 
induction of cell death in response to reactive oxygen species (ROS), ER stress, and other stimuli 
(189,190). The interaction of CIB1 with either of these kinases may contribute to the CIB1 
depletion-induced cell death observed in the data presented herein (see Figure 2-1). Taken 
together, these reports suggest that CIB1 may promote cell survival either by promoting AKT and 
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ERK activity, or via its interaction with SK1 or ASK1. Alternatively, perhaps the observed effects 
of CIB1 depletion rely on simultaneous aberration of a combination of these pathways. Further 
work should be done to explore potential synergism between these cell signaling pathways in the 
induction of cell death in response to CIB1 depletion. 
Because CIB1 is essential for TNBC survival and tumor growth, we asked whether CIB1 
expression is prognostic of TNBC patient survival. Recently CIB1 expression was reported to be 
relatively higher in hepatocellular carcinoma tumor center compared to non-tumorous liver tissues 
from 100 patient samples (141), as well as in breast cancer tissue compared to matched non-
cancerous breast tissue from nine patient samples (114). We found no association between CIB1 
mRNA expression and patient relapse-free survival in both TNBC and ER-negative breast cancer. 
In contrast to previous reports, our study used gene expression data from thousands of breast 
cancer patients across four established datasets (157,182-184). While the data presented here 
suggest that CIB1 expression is not prognostic in TNBC, it is possible that CIB1 does have 
prognostic implications in other types of cancer. Our results indicate that CIB1 expression is not 
predictive of TNBC patient prognosis, and further suggest that CIB1 overexpression does not 
promote tumorigenesis per se. 
CIB1 appears to have a critical role in promoting AKT activation and cell survival in cells 
reliant on the AKT oncogenic pathway. However, CIB1 itself has never been described as an 
oncogene. Although we find that CIB1 depletion is lethal to TNBC cells with high pAKT/low PTEN 
activity (Figure 2-10), CIB1 depletion is tolerated in non-cancerous cells, such as primary 
endothelial cells (133) and non-cancerous mammary epithelial cells (Figure 2-3), and in TNBC 
cells that do not rely on AKT signaling (Figure 2-1A). Furthermore, CIB1 knockout mice have no 
developmental defects (163), suggesting that CIB1 could be a potentially safe therapeutic target. 
The properties of CIB1 observed here are consistent with non-oncogene addiction, a 
phenomenon in which cancer cells require, or become ‘addicted’ to a non-mutated, non-
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overexpressed gene/protein that is nonetheless essential to maintain oncogenic signaling 
pathways (58,59). For example, ATM-deficient tumor cells display non-oncogene addiction to the 
enzyme DNA-dependent protein kinase catalytic subunit (DNA-PKcs), and DNA-PKcs has been 
identified as a potential drug target in ATM-defective malignancies (191). Based on this example, 
our data suggest that PTEN-defective TNBC tumors may display non-oncogene addiction to 
CIB1, implicating CIB1 as a novel drug target in TNBC. 
In summary, CIB1 inhibition induces TNBC cell death in cell culture and tumor regression 
in vivo. These results warrant further investigation of CIB1 in non-oncogene addiction and as a 
candidate for TNBC therapy. 
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Figure 2-10. Proposed mechanism of CIB1 regulation of TNBC cell survival and potential 
role of CIB1 in non-oncogene addiction. A) CIB1 promotes TNBC cell survival, proliferation, 
and tumor growth via AKT and ERK signaling pathways. B) CIB1 depletion results in loss of AKT 
and ERK. This effect is mediated in part by PAK1, but also likely involves additional, undetermined 
factors (dotted line). CIB1 depletion is most effective in PTEN-deficient cells and/or cells with 
elevated AKT activation. Because PTEN also acts as an upstream regulator of PI3K/AKT 
signaling, inactivating mutations or deletions of PTEN commonly result in hyper-activation of this 
pathway. Thus, TNBC cells with low or absent PTEN show increased sensitivity to CIB1 
depletion.  Together with the observations that CIB1 depletion/loss has minimal effect on non-
cancerous cells (133) or TNBC cells with wild-type PTEN, our findings suggest a role for CIB1 in 
the concept of non-oncogene addiction. Figure used with permission from (155). 
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2.4 Methods 
Cell lines and cell culture – Cell lines and cell culture conditions are listed in Table 2-2. 
Cell Line Media 
BT549 RPMI+10%FBS+10ug/mL Insulin 
HCC1143 RPMI+10%FBS 
HCC1937 RPMI+10%FBS 
Hs578T DMEM+10%FBS+10ug/mL Insulin 
MDA-231 DMEM+10%FBS 
MDA-436 DMEM+10%FBS+10ug/mL Insulin 
MDA-453 DMEM+10%FBS 
MDA-468 DMEM+10%FBS 
SUM102 DMEM/F12+5%FBS+10ug/mL Insulin+1ug/mL Hydrocortisone 
SUM149 DMEM/F12+5%FBS+10ug/mL Insulin+1ug/mL Hydrocortisone 
SUM159 DMEM/F12+5%FBS+10ug/mL Insulin+1ug/mL Hydrocortisone 
ZR-75-1 RPMI+10%FBS+10ug/mL Insulin 
SKBR3 McCoy’s5a+10%FBS 
ME16C MEBM (MEGM Bullet Kit: MEGM+BPE+hEGF+Hydrosortisone+Insulin 
All cell lines were grown at 37ᵒC in 5% CO2 humidified air. 
Table 2-2. Cell lines and cell culture conditions used in TNBC Panel. Table used with 
permission from (155). 
 
Mice and Xenografts – MDA-468-CIB1shRNA and MDA-468-SCRshRNA (5x106 cells) in PBS 
were mixed 1:1 with Cultrex Basement Membrane Extract Type III (Trevigen, Gaithersburg, MD) 
and injected subcutaneously into the flanks of 6-week old female Nu/Nu mice (Charles River 
Laboratories, Wilmington, MA). Mice were enrolled at a tumor size of ~100mm3 in the following 
treatment arms: 1% Sucrose (Sigma, St. Louis, MO), 1% sucrose + 2 mg/mL doxycycline (Sigma, 
St. Louis, MO); administered via drinking water 3x/week. Tumors were measured twice per week 
with calipers (tumor volume = length x width x width / 2). Mice were euthanized after 5 weeks of 
treatment and tumors were resected for further analysis. 
 58 
 
RNAseq analysis – MDA-468_SCRshRNA and MDA-468_CIB1shRNA cells were treated with 
doxycycline for <96 hours. After removing dead cells, RNA was isolated from viable cells (RNeasy 
kit, Qiagen, Venlo, Netherlands), and cDNA generated (QuantiTect Reverse Transcription kit, 
Qiagen). cDNA was sequenced at the UNC High Throughput Sequencing Facility on an Illumina 
HiSeq 2000 (Illumina, San Diego, CA). Differential gene expression analysis was performed using 
DESeq2 (192) and differentially expressed genes were selected based on Log2 fold change ≥ ± 
2 and Benjamini-Hochberg adjusted p-value < 0.05. Lists of differentially expressed genes are 
displayed in Appendices A (upregulated genes) and B (downregulated genes). Differentially 
expressed genes were analyzed using Ingenuity Pathway Analysis (Qiagen). The median-
centered gene expression dataset and methods from Prat et al (156) were used for Significance 
Analysis of Microarrays on the CIB1 KD sensitive versus insensitive cell lines, and for the 
identification of cell line Differentiation Scores; both of these analyses were performed with R 
version 3.1. To identify other gene signatures with similar profiles in human breast tumors (182), 
10,508 gene signatures were retrieved from the GSEA database and via manual curation, each 
signature score was identified for each tumor by taking the average value of all signature genes 
within the median-centered gene set, then Pearson Correlation Values were obtained in Excel 
contrasting the CIB1 KD signature with all signatures.   
Colony formation assay – MDA-468-control and -CIB1shRNA cells were treated ± 1 μg/ml Dox 
for 48 hours prior to plating at a density of 2000 cells/well.  Cells were allowed to grow 9 days in 
the absence or presence of Dox, with media changes every 4 days.  Cells were stained with 
crystal violet (0.05% w/v in 4% formaldehyde) (Sigma, St. Louis, MO) and colonies counted using 
ImageJ software. 
RNA interference – Cells were transduced with either control shRNA 
(ACCGCTCTTCACACAGATCCTCTTCAAGAGAGAGGATCTGTGTGAAGAGCTTTTTC), CIB1 
shRNA 1 
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(ACCGTGCCCTTCGAGCAGATTCTTCAAGAGAGAATCTGCTCGAAGGGCACTTTTTC), or 
CIB1 shRNA 2, (CAGCCTTAGCTTTGAGGACTTCTCGAGAAGTCCTCAAAGCTAAGGCTG). 
For inducible RNAi experiments, MDA-468 cells were transduced with either inducible control 
shRNA (GCTACACTATCGAGCAATTTTGGATCCAAAATTGCTCGATAGTGTAGC) or inducible 
CIB1 shRNA (GGCTTAGTGCGTCTGAGATTTGGATCCAAATCTCAGACGCACTAAGCC) using 
the pLV-H1-TetO-Puro lentiviral plasmid (Biosettia, San Diego, CA). Lentiviral particles were 
prepared as described previously (96). 
Cell proliferation and cell death assays – MDA-468-CIB1shRNA and MDA-468-SCRshRNA 
cells were plated at 3x105 cells per 10cm dish, treated ± Doxycycline, and allowed to grow for 3, 
5, or 7 days. Cells were harvested by trypsinization and counted using a hemacytometer. Cell 
viability was determined by trypan blue exclusion. 
Flow cytometry – Cells were grown in the presence of Doxycycline for 5 days. MDA-468-
CIB1shRNA and MDA-468-SCRshRNA cells were detached using 2 mM EDTA and 5x105 cells 
were stained with FITC Annexin V (BD Biosciences), 7-AAD (eBioscience), or the combination of 
FITC Annexin V and 7-AAD according to the BD FITC Annexin V Apoptosis Detection Kit protocol. 
Data was collected from 104 cells using a FACS Canto flow cytometer (BD), then analyzed using 
FACS Diva software (BD). 
Histology and microscopy – Fixed tumors were paraffin embedded, slides were cut and H&E 
staining completed by the Lineberger Comprehensive Cancer Center Animal Histopathology Core 
Lab. TUNEL assay was performed according to manufacturer’s protocol (Promega). Microscopy 
was performed using an Olympus BX61 Wide Field Microscope at the UNC Microscopy Services 
Laboratory. 
Kaplan-Meier survival analyses – Data from (157,182-184) were downloaded and processed 
as in (193). Kaplan-Meier survival analyses and Log-Rank p-values were performed with Winstat. 
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Tumors were ranked from lowest to highest based on CIB1 expression levels and divided into two 
equal groups based on CIB1 gene expression. 
Constitutively active PAK1 expression – Constitutively active PAK1 (caPAK1) harboring 
activating mutations L107F and T423E was cloned into the pCDH-EF1-MCS-T2A-Puro vector 
(System Biosciences, Mountain View, CA). Lentiviral particles were produced as described 
previously (96). MDA-468 cells were transduced with caPAK1, then after 48 hours cells were 
transduced with either CIB1 shRNA or Control shRNA. Cells were harvested 96 hours after 
shRNA treatment and counted. Cell viability was determined by trypan blue exclusion. 
Western blotting – Cell and tumor lysates were prepared using CHAPS lysis buffer (20 mM 
HEPES, 150 mM NaCl, 5% v/v glycerol, 10 mM CHAPS, 0.1 mM CaCl2, 0.05 mM MgCl2, 20 mM 
NaF, 10 mM β-Glycerophosphate, 0.1 mM Sodium Pervanadate, 1.25 mg/mL N-Ethylmalemide, 
and Protease Inhibitor Cocktail III (BioVision). Protein concentration of tumor lysates was 
determined using BCA Assay (Thermo Scientific), equal amounts of total protein were separated 
by SDS-PAGE, transferred to PVDF, and incubated with indicated primary antibodies overnight 
at 4oC, and visualization was performed using ECL2 (Pierce). The following antibodies were used: 
CIB1 chicken polyclonal antibody was produced as described previously (86); antibodies against 
pAKT473 (9271), pERK (9101), total AKT (4691), and γH2Ax (9718) were obtained from Cell 
Signaling Technology (Danvers, MA); ERK polyclonal (sc-94), PTEN (sc-9145) and PAK1 (sc-
882) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX); Rac monoclonal 
antibody was purchased from EMD Millipore (Billerica, MA). 
Statistical analysis – P-values were calculated using Student’s T-test. 
  
 61 
 
 
CHAPTER 3: CIB1 BINDS α-INTEGRIN CYTOPLASMIC TAILS IN VITRO AND IN CELLS 
 
3.1 Introduction 
Integrins are transmembrane cell adhesion receptors that form a critical link between the 
cellular cytoskeleton and extracellular matrix, and also have important roles in cell adhesion, 
migration, and signal transduction (194). Normal integrin function is essential in development, 
immune response, hemostasis, and cancer (194-198). Therefore, integrin structure, function, and 
binding partners have been studied intensively toward increased understanding of relevant 
biological processes and diseases. 
3.1.1 Integrin activation and signaling is regulated by cytoplasmic binding proteins.  
Integrin-dependent signaling pathways are precisely regulated to maintain physiological 
behavior. Integrins are heterodimeric receptors composed of an α subunit and a β subunit, and 
have a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. 
Transmission of signals through the cell membrane via integrins is regulated by the binding of 
cytoplasmic proteins to the integrin tails. For example, kindlin and talin are cytoplasmic proteins 
that bind to integrin β-subunit cytoplasmic tails and have important roles in integrin activation 
(199-201).  
3.1.2 CIB1 may modulate integrin-dependent cell function and signaling.  
The Parise lab discovered CIB1 as a binding partner of integrin αIIb, and initially published 
that CIB1 bound to αIIb, but not other integrin α-subunits (68). Integrin αIIb is expressed 
exclusively on platelets and megakaryocytes, but CIB1 expression is ubiquitous 
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(70,108,111,118). CIB1 binding to αIIb regulated integrin αIIb agonist-induced signaling and 
function (81). Additional studies revealed that CIB1 bound to αIIb in a highly conserved domain 
spanning the transmembrane and cytoplasmic domains of the integrin (69,70). Because CIB1 
binds a conserved region of αIIb and is ubiquitously expressed, we hypothesized that CIB1 may 
bind additional integrins and have a broader role in integrin biology.  
3.1.3 Exploring CIB1-integrin binding in vitro and in cells 
The binding of CIB1 to α-integrin cytoplasmic tail peptides was tested by several in vitro 
binding assays. The Kd for CIB1 binding to 8 different integrin peptides was determined by 
isothermal titration calorimetry, with a maximum Kd of 23.5μM (αM) and a minimum Kd of 0.9μM 
(α2), and the interactions were further tested by competitive binding assays to measure the ability 
of various α-integrin peptides to compete with αIIb for CIB1 binding (124). These results 
demonstrated that CIB1 is capable of binding to multiple α-integrin subunits. I asked whether 
CIB1-integrin binding is physiologically relevant, and explored this question through biochemical 
and cell-based assays. Here I present evidence that CIB1 interacts with specific residues in the 
transmembrane domain of the integrin cytoplasmic tail, and that CIB1 can access these residues 
in the presence of a cell membrane. I present additional data to support the functional 
consequences of CIB1 binding to integrin in cells. Finally, I discuss the relevance of these findings 
to cell biology and to broadly understanding CIB1 function in human health and disease.  
3.2 Results 
3.2.1 CIB1 binds α-integrin tails via a conserved region spanning the transmembrane and 
cytoplasmic tail domains of the integrin 
Previous evidence demonstrated that CIB1 binds to integrin αIIb at a region spanning the 
transmembrane and cytoplasmic tail domains (See Figure 3-1) (69). To determine α-integrin 
residues that were essential for CIB1 binding, I designed α-integrin cytoplasmic tail peptides 
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harboring alanine substitutions. A thirteen amino acid region of integrin αIIb was shown to contain 
critical residues for CIB1 binding (69). Based on the homology between αIIb and αV (124), I 
hypothesized that this region was essential for CIB1-αV binding as well. To test this hypothesis, I 
measured the binding affinity of CIB1 to αV peptides using isothermal titration calorimetry (Figure 
3-1). I generated four mutants with two, four, and six alanine substitutions at the N-terminus of an 
αV cytoplasmic tail peptide. Binding of CIB1 to alanine-substituted αV peptides was compared to 
CIB1 binding to αV-WT. The binding affinity for CIB1 and αV WT was 2.8 μM. Alanine substitutions 
at positions 1011-1012, or at positions 1013-1014 did not significantly affect binding affinity. 
However, combining these mutations to generate an αV-4A  mutant (1011LVFV/AAAA) significantly 
reduced binding affinity. An αV-6A mutant peptide similarly lacked detectable binding to CIB1. 
Interestingly, neither of the αV2A mutants significantly affected CIB1-αV binding, but the αV-4A 
mutant completely lost CIB1 binding ability. These data suggest that hydrophobic residues in the 
putative transmembrane region of integrin αV are critical for CIB1 binding to the αV cytoplasmic 
tail.  
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Figure 3-1. CIB1 binding to integrin αV cytoplasmic tail peptides is disrupted by alanine 
substitutions in the transmembrane region of the putative CIB1 binding domain. A) Amino 
acid sequences of αV peptides used in ITC experiments. The putative CIB1 binding domain 
(determined by Barry et al. 2002) is boxed. A dotted line separates residues in the transmembrane 
region from residues in the cytoplasmic region. B) Model of the integrin αV transmembrane and 
cytoplasmic tail domains. The transmembrane region and N-terminal portion of the cytoplasmic 
tail of the integrin form an α-helix. C) Isotherm (upper panel) and integrated peaks fit with one site 
binding model (lower panel) of αV WT binding to CIB1. D) Table of binding affinities for CIB1 
binding to WT and alanine-substituted αV CTs. αV 4A and αV 6A have binding affinities outside 
of the detectable limit by ITC (100 μM). Some of the data presented in C-D was published in 
Freeman et al. and reprinted with permission from (124). Copyright 2013 ACS. 
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3.2.2 CIB1 can access integrin αV membrane proximal residues in the presence of a 
physiologically relevant lipid bilayer 
Because CIB1 binds to αV at a region spanning the cytoplasmic and transmembrane 
domains, it is possible that the cell membrane physically impedes CIB1 from accessing its αV 
binding domain inside a cell. We hypothesized that CIB1 can access its binding site on the 
integrin, even when the integrin is embedded in a lipid bilayer membrane. To test this hypothesis 
we embedded integrin αV polypeptides into nanodiscs, soluble lipid bilayer discs, and tested CIB1 
binding to integrin αV via pulldown assays (Figure 3-2).  
Nanodiscs were assembled containing either αIIb WT, αIIb 2A, αIIb 4A, or αIIb 6A, or no 
integrin (empty nanodiscs). Nanodiscs were mixed with purified recombinant CIB1, then pulled 
out of solution using Ni2+ beads to bind the histidine-tagged MSP1 protein. Protein complexes 
were eluted off the beads and eluted proteins were detected by Western blot. I found that CIB1 
binds to αIIb WT nanodiscs, but not empty nanodiscs (Figure 3-3B). I then compared the binding 
of CIB1 to αIIb mutant nanodiscs and found that CIB1 bound to αIIb 2A nanodiscs, but that binding 
was significantly reduced to αIIb 4A and αIIb 6A nanodiscs (Figure 3-3C). These results mirror 
the ITC binding data generated for CIB1 binding to α-integrin peptides. Because the mutated 
residues reside in the membrane-spanning region of the integrin, the results support the 
hypothesis that CIB1 can access its integrin binding site even when the integrin is embedded in 
a lipid bilayer.  
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Figure 3-2. Nanodisc structure and synthesis. A) Nanodiscs are produced by mixing 
membrane scaffolding protein (MSP, yellow & orange), phosphatidylcholine/phosphatidylserine 
(white), and integrin C-terminus (green and purple). The integrin C-terminus is composed of the 
transmembrane and cytoplasmic tail regions of the integrin. Nanodisc self-assembly results in the 
integrin embedding itself into the lipid bilayer to protect the hydrophobic transmembrane domain. 
**Image generated by Thomas Freeman. B) Negative-stain electron microscopy of pre-
assembled nanodiscs. Each white circle is an individual nanodisc with diameter ~10 nm.  
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Figure 3-3. CIB1 binding to membrane-embedded α-integrin subunits is disrupted by 
mutations in the C-terminal portion of the integrin transmembrane domain. A) Model of the 
integrin αIIb transmembrane and cytoplasmic tail domains. B) CIB1 binds to αIIb WT nanodiscs, 
but not to empty nanodiscs. C) CIB1 binds to nanodiscs containing αIIb-2A, but not to αIIb-4A or 
αIIb-6A.  
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Although preliminary results from CIB1-nanodisc binding assays were encouraging, we 
encountered technical hurdles that impeded further experimentation and data collection. These 
technical challenges stem from the goal to reduce non-specific binding, a challenge inherent in 
binding assays. Several attempts were made to reduce non-specific binding of CIB1 to empty 
nanodiscs or free protein in these assays, to enable accurate measurement of CIB1 binding to 
membrane-embedded integrin. I will outline here several challenges, respective troubleshooting 
steps, and outcomes.  
The first challenge addressed was to optimize the assay buffer for nanodisc pulldown 
experiments. The base buffer, TBS (20 mM Tris, 150 mM NaCl in dH2O), was supplemented with 
30 mM imidazole, 5% glycerol, 10% glycerol, or a combination of imidazole plus glycerol, and 
CIB1 binding to empty nanodiscs was measured in each buffer to determine optimum conditions 
to reduce non-specific binding. Experiments performed in TBS supplemented with imidazole and 
10% glycerol demonstrated the lowest signal of CIB1 binding to empty nanodiscs, but the addition 
of glycerol had only modest effects compared to the addition of imidazole alone. Therefore, TBS-
I buffer (TBS plus 30mM imidazole) was used for all subsequent experiments. 
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Figure 3-4. Nanodisc challenges and troubleshooting. A) Nanodisc preparations typically 
resulted in a mixed population of three species: Empty nanodiscs, MBP-integrin embedded 
nanodiscs, free MBP-integrin. As all three species carried a hexahistidine tag, the species are 
difficult to differentiate by affinity chromatography. TM = transmembrane domain; CT = 
cytoplasmic tail domain. B) Flow chart of experimental pathways to troubleshoot nanodisc 
challenges. Path 1: 134. Purified MSP1 and MBP-integrin are mixed with membrane lipids, 
nanodiscs are assembled and the products are purified by affinity chromatography. Path 1 results 
in the 3 species described in (A). Path 2: 1234. Purified MBP-integrin is subjected to TEV 
cleavage to remove MBP, nanodiscs are assembled, and purified by affinity chromatography. Due 
to incomplete TEV cleavage, Path 2 results in all of the products in (A) plus cleaved integrin 
embedded in nanodiscs. Path 3: 135. Purified proteins were assembled into nanodiscs and 
purified by size-exclusion chromatography to remove empty nanodiscs and free MBP-integrin.  
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Testing for differential binding of CIB1 to WT or mutant integrin peptides embedded in 
nanodiscs introduced additional challenges and troubleshooting. The nanodiscs consisted of 
purified proteins MSP1 (membrane scaffold protein) and integrin peptides linked to MBP (maltose 
binding protein) organized with lipids into nanodisc complexes. Integrins were linked to MBP to 
facilitate expression and purification from E. coli. During nanodisc preparation, a mixed population 
of products was produced including integrin nanodiscs, empty nanodiscs, and free protein in 
solution (Figure 3-4). Because both MSP1 and MBP had a hexahistidine tag at the N-terminus of 
the protein, it was impossible to distinguish between the different populations during preparation, 
purification, and binding assays. This mixed population made experimental results difficult to 
interpret. To overcome these challenges, I attempted to cleave the MBP from purified MBP-
integrin using TEV (Tobacco Etch Virus) protease followed by a negative selection using amylose 
resin to bind His-MBP. While this technique reduced the amount of MBP-integrin in solution, the 
cleavage reaction and purification did not reach 100% efficiency, as evidenced by the signal from 
integrin, MBP and MBP-integrin in the flow through, wash, and bead samples (Figure 3-5A).  
Due to the persistent inability to completely cleave the His-MBP from the integrin peptide, 
I opted to pursue a different approach to obtain a pure population of integrin-embedded 
nanodiscs. Purified MBP-integrin, MSP1, and lipids were assembled into nanodiscs and then 
separated by size-exclusion chromatography. Two major peaks were observed. In each sample, 
the second peak corresponded to the predicted molecular weight of the nanodiscs in the sample 
(~150 kDa for empty nanodiscs, ~190 kDa for integrin-embedded nanodiscs) (Figure 3-5B). 
Fractions from these peaks were run on a gel and subjected to Western blotting to confirm that 
the fractions contained both MSP1 and MBP-integrin, suggesting that these fractions contained 
intact nanodiscs (data not shown). Unfortunately, the size exclusion chromatography was not 
sensitive enough to separate integrin-embedded nanodiscs from empty nanodiscs. In addition, 
when free MBP-integrin was run through the column, a single peak at ~350 kDa was observed 
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(data not shown), approximately 7x the predicted molecular weight of MBP-integrin, which differs 
from the molecular weight observed by gel (Figure 3-5). Therefore, size exclusion 
chromatography was was unable to effectively separate empty nanodiscs, MBP-integrin 
nanodiscs, and free MBP-integrin in solution. Despite multiple approaches, a homogenous 
population of integrin-embedded nanodiscs was never achieved and the results of binding assays 
were inconclusive. 
Future nanodisc experiments should be designed to more thoroughly explore the CIB1-
integrin interaction in the presence of a membrane. To avoid the technical challenges described 
herein, a better experimental design should be considered in which the proteins used in the assay 
carry different tags, thus enabling easier differentiation of species in binding assays. For example, 
using a biotinylated MSP would result in nanodiscs with a biotin tag, facilitating easy binding to 
streptavidin. To detect CIB1-integrin binding, simple in vitro pulldown assays (for example, using 
streptavidin beads to isolate biotinylated nanodiscs) could be designed to detect CIB1-integrin 
binding. These experiments could be followed by a more quantitative approach, such as surface 
plasmon resonance. For example, using Biacore terminology, the nanodiscs could be immobilized 
to a streptavidin chip as the “ligand”, then CIB1 could be flowed over the chip as the “analyte” to 
quantitatively measure CIB1 binding to membrane-embedded integrin, as in (202,203). Finally, 
generation of smaller nanodiscs (i.e. with fewer lipid molecules) has enabled the use of NMR to 
solve solution structures of proteins in complex with a membrane-bound binding partner 
(204,205). In this case, NMR could be utilized to create a 3-dimensional structure of CIB1 binding 
to the integrin in the presence of a cell membrane, to determine how CIB1 accesses its putative 
binding site, and allow functional inferences to CIB1 function in cell biology.   
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Figure 3-5. Cleavage and purification of MBP-αIIb and purification of nanodiscs. MBP-αIIb 
was subjected to cleavage by TEV protease and cleavage products were purified and run on a 
gel. Lanes: 1 – Pre-cleavage sample; 2 – Cleavage product; 3 – Flow-through; 4 – Wash; 5 – 
Beads. Cleavage reaction and amylose purification are inefficient at separating MBP-αIIb from 
cleaved αIIb. B) Size-exclusion chromatography of assembled nanodiscs. Chromatography 
successfully generated peaks at the appropriate predicted molecular weight of nanodiscs (Empty 
nanodiscs – 150 kDa; Integrin-embedded nanodiscs – 190 kDa).   
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3.2.3 Integrin mutants may affect CIB1-integrin function in cells 
CIB1 regulates signaling through pathways that are also activated downstream of ligand 
binding to integrins (196). For example, our lab recently found that CIB1 is an upstream regulator 
of both ERK and AKT signaling pathways (96). However, it is unknown whether αv-dependent 
activation of these same pathways requires CIB1 or whether it is a parallel event, independent of 
CIB1. CIB1 is known to regulate activation of the related integrin αIIbβ3 (81), but the effect of 
CIB1 on αvβ3 activation or downstream signaling has never been studied. 
In addition to its interaction with integrin αIIb (69,70,81), we demonstrated that CIB1 co-
immunoprecipitates with integrins αV and α5 from whole cell lysates (Figure 3-6) (124). Since I 
found that introduction of amino acid substitutions in the CIB1 binding domain on the integrin 
disrupted CIB1-integrin binding in vitro, I asked whether these mutations to the full-length integrin 
had any effect on CIB1-integrin binding and function in cells. I hypothesized that cells expressing 
mutant integrin αV 4A would have impaired signaling and integrin-mediated adhesion, compared 
to cells expressing αV WT. 
To explore the role of CIB1 binding to integrin αV in cells, I expressed full length integrin 
αV (WT or mutant) in the αV-null cell line M21L (206), and generated stable cell lines expressing 
either αV WT (M21L-αV WT), αV 2A (M21L-αV 2A), or αV 4A (M21L-αV 4A). To test whether αV 
mutations could disrupt CIB1-αV interaction in cells, I measured CIB1-αV binding via co-
immunoprecipitation experiments. I immunoprecipitated CIB1 from whole cell lysates of M21L-αV 
WT, M21L-αV 2A, and M21L-αV 4A, and probed the immunoprecipitates for integrin αV by 
Western blot. As expected from in vitro binding experiments, I found that that less αV 4A co-
immunoprecipitated with CIB1 than αV WT (Figure 3-7). Surprisingly, more αV 2A co-
immunoprecipitated with CIB1 than αV WT, suggesting that the αV 2A mutant may enhance CIB1-
αV binding in cells (Figure 3-7).  
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Figure 3-6. Integrins αV and α5 co-immunoprecipitate with CIB1. HEK293T cells were 
transfected with cDNA encoding integrin αV. Endogenous CIB1 was immunoprecipitated from 
integrin αV-transfected or integrin α5-transfected cell lysates. This figure is adapted from Freeman 
et al. and used with permission from (124). Copyright 2013 ACS. 
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Figure 3-7. Integrin αV mutations alter CIB1-αV binding in cells. A) CIB1 was 
immunoprecipitated from M21L cells overexpressing αV WT, αV 2A, or αV 4A. 
Immunoprecipitates were probed by Western blotting for the presence of αV. Whole cell lysates 
were also run to compare relative levels of overexpressed αV. B) Densitometry of Western blot in 
(A). Approximately 2.5 times as much αV 2A immunoprecipitated with CIB1 as αV WT. Less than 
half as much αV 4A immunoprecipitated with CIB1 compared to αV WT. 
  
 76 
 
3.2.4 CIB1 binding to integrin αV may affect cell signaling and proliferation 
Integrin αVβ3 binds to the extracellular matrix component vitronectin. To test whether 
disruption of CIB1-αV binding affects cell adhesion, I plated M21L-αV WT and M21L-αV 4A cells 
on vitronectin and measured cell adhesion using a centrifugation-based adhesion assay. I found 
no difference in M21L cell adhesion to vitronectin after 30, 60, or 90 minutes between M21L-αV 
WT and M21L-αV 4A cells (Figure 3-8A).  
In addition to cell adhesion, integrins transmit signals from the extracellular environment 
to the inside of the cell and thereby promote cellular processes including cell proliferation. To 
determine whether CIB1-αV binding affects cell proliferation, I plated equal numbers of M21L-αV 
WT/2A/4A and then measured total cell number after three days of growth. While the results show 
that there is not a statistically significant difference in cell proliferation between the cell types, the 
results trend towards a decrease in proliferation in cells expressing αV 2A, and trend toward an 
increase in proliferation in cells expressing αV 4A (Figure 3-8B).  
To explore whether CIB1-αV binding affects cellular signaling, I examined ERK 
phosphorylation in M21L-αV WT/2A/4A cells plated on vitronectin. Cells were plated on vitronectin 
to focus the cell signaling response to integrin αV-mediated signaling. Cells were harvested at 30, 
60, and 180 minutes after plating on vitronectin, then lysed and analyzed by Western blot, and 
signals quantified by densitometry. Although the relative ERK phosphorylation was not statistically 
significant between different cell types, cells expressing αV 4A trended towards increased ERK 
phosphorylation, whereas cells expressing αV 2A trended towards decreased ERK 
phosphorylation (Figure 3-8C).  
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Figure 3-8. Integrin αV mutants may affect cell proliferation and cell signaling. A) Adhesion 
assay. M21L-αV WT and M21L-αV 4A cells were plated on vitronectin coated-plates and allowed 
to adhere for 30, 60, or 90 minutes. The relative percent of adherent cells was determined. No 
difference was observed between cells expressing αV WT and cells expressing αV 4A. B) 
Proliferation assay. M21L-αV WT/2A/4A cells were allowed to grow in cell culture and total cell 
number was assessed three days after plating. Though the difference in average cell number was 
not statistically significant between cell types, the data trend toward an effect of integrin mutants 
on cell proliferation. Data represent the average total cell number ± SEM. N = 5 (WT/4A); N = 3 
(2A). C) Relative phosphorylation of ERK in M21L-αV WT/2A/4A cells plated on vitronectin. Cells 
were plated on vitronectin and then harvest 30, 60, or 180 minutes after plating. Cell lysates were 
analyzed by Western blot for relative levels of ERK phosphorylation and blots were quantified by 
densitometry. Although the difference between cell types was not statistically significant, cells 
expressing αV 4A trend toward increased pERK, whereas cells expressing αV 2A trend toward 
decreased pERK, relative to αV WT. N = 3.  
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3.2.5 CIB1 binds to different integrin α subunits via distinct residues in the CIB1 hydrophobic 
pocket 
CIB1 interacts with α-integrin subunits via a hydrophobic binding pocket (71,72). The C-
terminus of CIB1 forms an α-helix that, in the absence of a binding partner, lays in the hydrophobic 
pocket (75). The CIB1 structure based on a homology model of calcineurin B, an EF-hand 
containing protein relative of CIB1, demonstrates how the C-terminal helix may undergo a 
conformational shift to enable integrin binding to the CIB1 hydrophobic pocket (207). I utilized this 
structure to explore CIB1 binding to α-integrin peptides.  
To determine whether CIB1 makes unique contacts with different α-integrin subunits, 
Freeman et al. performed all-atom replica exchange discrete molecular dynamics (DMD) 
simulations to model CIB1 binding to integrin αIIb and αV subunits (124). Using the lowest energy 
structures from the simulations, residues on CIB1 were identified that make contact with integrin 
αIIb and integrin αV. Nine residues in the CIB1 hydrophobic pocket contact αIIb and twelve 
residues contact αV. Notably, unique residues made contact with each integrin subunit, 
suggesting that CIB1 interacts with each integrin subunit via different residues in the hydrophobic 
pocket (Figure 3-9) (124). 
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Figure 3-9. CIB1 makes unique contacts with different α-integrin subunits. Discrete 
molecular dynamics simulations of CIB1 binding to integrin αIIb (A, yellow) or αV (B, cyan). 
Figures represent lowest energy structures from molecular docking of integrin peptides to CIB1. 
CIB1 is shown in gray and residues making contact with the integrin peptide are colored red. 
Different residues make contact with each individual integrin peptide. This figure is adapted from 
work published by Freeman et al (124).  
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Since CIB1 makes unique contacts with different α-integrin subunits, I hypothesized that 
alanine substitutions to residues in the CIB1 hydrophobic pocket would affect the docking of 
integrin peptides to CIB1. To test this hypothesis, I generated alanine mutations in the CIB1 
structure used for DMD simulations (PDB file 1DGU) at the residues that made contact with the 
integrins in the DMD simulations (see Figure 3-10B). I then performed docking simulations to 
determine whether the alanine substitutions affected integrin peptide docking to CIB1 (Table 3-
1). 
Several CIB1 mutants were further tested by Tina Leisner using in vitro pulldown assays 
with MBP-integrin cytoplasmic tail fusion proteins (124). Mutants 152LI/AA and 173F/A weakened 
CIB1 binding to αIIb, but had minimal effect on CIB1 binding to αV, whereas 114 IFDF/AADA 
greatly reduced CIB1 binding to αV with no detectable change in CIB1-αIIb binding (Figure 3-
10A). Two of these mutants, 173F/A and 114 IFDF/AADA, had opposite results in in vitro binding 
assays as they did in the DMD simulations. Thus, although the predictions generated from the 
DMD simulations are interesting, more direct binding assays must be carried out to determine the 
effect of CIB1 mutations on CIB1-integrin binding. To better understand the cellular phenotypes 
of mutations to the CIB1 hydrophobic pocket, cell-based assays were attempted by expressing 
full length WT CIB1 and CIB1 mutants in CIB1 deficient cells;  however these assays were 
unsuccessful due to decreased expression of CIB1 mutants relative to WT CIB1 (Figure 3-10C). 
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Table 3-1. Effect of CIB1 mutations on CIB1-integrin binding by DMD simulations. CIB1 
mutants were docked with integrin αV and integrin α5 peptides and lowest energy state was 
compared to docking to WT CIB1, then displacement of peptides was assessed.  
  
CIB1 mutation Disrupt integrin αV binding? 
Disrupt integrin 
α5 binding? 
114IFDF/AADA No Yes 
114IFDF/AADA+173F/A No No 
115A/S No No 
131LVNCL/AANCA Yes No 
131LVNCL/AANCA+173FQHI/AQHA Yes Yes 
135L/A No No 
135L/N No No 
173F/A Yes No 
173FQHI/AQHA Yes Yes 
177I/A Yes Yes 
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Figure 3-10. Alanine substitutions in the CIB1 hydrophobic pocket disrupt CIB1 binding to 
α-integrin peptides. Purified CIB1 WT and three CIB1 mutants (152 LI/AA, 114 IFDF/AADA, 173 
F/A) were mixed with MBP-αIIb or MBP-αV. MBP was pulled down and binding partners were 
analyzed by Ponceau-S staining (MBP-αIIb and MBP-αV) or Western blot (CIB1). A) CIB1 152LI/AA 
lacked binding to αIIb and slightly reduced binding to αV. CIB1 114IFDF/AADA lacked binding to αV, 
but maintained normal binding to αIIb. CIB1 173F/A had slightly reduced binding to αIIb, but no 
effect on αV. Panel A was adapted from a figure published by Freeman et al (124). B) Structural 
models of each CIB1 mutant with mutations highlighted in red. All three mutations are in the 
hydrophobic binding pocket at locations predicted to make contact with integrin peptides in DMD 
simulations. C) Western blot of lysates of cells expressing either WT or mutant CIB1. CIB1 114 
IFDF/AADA and 173 F/A have lower expression than WT CIB1. Tubulin is included as a loading 
control.   
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3.3 Discussion 
Integrin function is critical to cell biology, and there is a need to better understand the 
intracellular mechanisms by which integrins are regulated and through which integrins perform 
their various functions. Integrin αV is one integrin of particular interest due to its role in vascular 
biology and its upregulation on many cancer cells.  
I explored the molecular interaction between CIB1 and the integrin αV subunit, and the 
functional effects of this interaction in cells. Until recently, CIB1 was considered to be a binding 
partner of one integrin, αIIb. Freeman et al. demonstrated that CIB1 binds to additional integrin 
subunits both in vitro and in cells. I explored the significance of specific amino acid residues in 
the putative CIB1-binding domain on the integrin. Specifically, residues αV-1011LVFVMY and 
αIIb-1014LVLAMW were examined by introducing amino acid substitutions/mutations to these 
residues and measuring the effect on CIB1-integrin binding by ITC and nanodisc pulldown 
experiments. These experiments revealed that α-integrin amino acid residues at the C-terminus 
of the transmembrane portion of the integrin are essential for CIB1 binding to αV and αIIb. This 
finding is significant because under normal conditions, these residues are embedded in the cell 
membrane near the interface of the membrane and cytoplasm. These findings may suggest that 
CIB1 embeds itself into the cell membrane in order to access its binding site on the integrin. 
Alternatively, the integrin may shift conformation in order to expose transmembrane residues and 
enable CIB1 to access its binding domain. Further experiments should be designed to better 
understand the structure of CIB1-integrin binding in a membrane environment. For example NMR 
may be used to determine the structure of the CIB1-integrin complex in nanodiscs, and potentially 
garner mechanistic insights into the role of CIB1 in integrin activation and signaling.  
The role of CIB1 binding to integrin αIIb has been explored previously in platelets and 
megakaryocytes (platelet precursor cells) (81,83), but despite the ubiquitous expression of CIB1, 
the role of CIB1 binding to additional integrins has not been explored previously (124). I generated 
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integrin αV mutants and expressed wild-type and mutant αV subunits in the αV-deficient cell line 
M21L. The M21L-αV 4A cells had reduced CIB1-αV binding, as expected. Surprisingly, the M21L-
αV 2A cells had more CIB1-αV binding compared to M21L-αV WT cells. These results may 
suggest that αV 2A binds to CIB1 with greater affinity than αV WT (although ITC and nanodisc 
pulldown in vitro assays do not confirm this finding). Regardless, this finding provided a unique 
opportunity to examine the differential effects of more/less CIB1-αV binding on cell proliferation 
and cell signaling. Although the results reported here did not reach statistical significance, the 
trends observed are worthy of discussion. M21L-αV 4A cells trended towards higher pERK 
signaling and proliferation. Conversely, M21L-αV 2A cells trended towards lower pERK signaling 
and reduced proliferation. One explanation of these results could be that CIB1-integrin binding 
per se reduces ERK activation and cell proliferation. However, an alternative explanation may be 
that when CIB1 is occupied by integrin αV 2A, it is less available to interact with other binding 
partners, such as PAK1, and promote ERK signaling and proliferation. Conversely, the αV 4A 
mutant reduced CIB1 binding, suggesting that more CIB1 is free in the cytoplasm to interact with 
PAK1 and other binding partners and promote ERK activation and cell proliferation. In this context, 
the results presented here predict that a CIB1 small molecule or peptide inhibitor may reduce cell 
signaling and cell proliferation. When considered with the data presented in Chapter 2, these data 
further confirm CIB1 as a target for cancer therapy.  
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3.4 Methods 
Methods utilized here were performed as described previously (124), unless otherwise noted.  
Protein purification and peptide synthesis – Human wild type CIB1 was cloned into pProEX 
HTc (Invitrogen), and further modified to include an upstream amino-terminal hexahistadine tag 
followed by a tobacco etch virus (TEV) cleavage site to facilitate removal of the hexahistadine 
tag.  CIB1 mutants 114IFDF/AADA, 152LI/AA, and 173F/A were made as previously described (208).  
MSP1 plasmid was obtained from Stephen Sligar. MBP-αIIb WT and mutant genes were 
generated by PCR-amplifying the C-terminus of αIIb and cloning into the pQE-MBP expression 
vector. MSP1, MBP-αIIb WT and mutants, and CIB1 WT and mutants were expressed and 
purified from E. coli BL21(DE3) as described previously with slight modifications as follows (209).  
After harvesting the cells, lysing by sonication, and centrifugation, clarified cell lysate was loaded 
onto an AKTA Purifier UPC 100 fitted with a 20 mL His-Prep FF 16/10 column (GE Healthcare).  
Fractions containing CIB1 were pooled and dialyzed in storage buffer (50 mM HEPES (pH 7.4), 
150 mM NaCl, 10% (v/v) glycerol, and 100 µM CaCl2).  The 6xHis tag was removed by proteolysis 
using His-tagged TEV, which was added at approximately 1 mg/100 mg of CIB1 along with 1 mM 
DTT, and 0.5 mM EDTA.  Cleavage was carried out overnight at room temperature.  Mature CIB1 
was isolated by subtractive Ni2+ affinity purification, where His-TEV was bound to the column, and 
CIB1 was collected in the flowthru.  The DTT and EDTA was removed by dialysis in storage buffer.   
Protein concentration of mature CIB1 was measured by absorbance at 280 nm and ε = 2980 cm-
1 M-1. 
Peptides were synthesized by either Bio-Synthesis, Inc. or via the High-Throughput 
Peptide Core and Arraying Facility at UNC-CH and purified by high performance liquid 
chromatography (HPLC).  Peptide mass was confirmed by MALDI MS/MS on a 7400 Proteomics 
Analyzer (Applied Biosystems). Sequences used are listed in Figure 3-1A. 
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To generate cytoplasmic tails that could be precipitated with amylose resin beads, DNA 
encoding either residues 1014-1039 of human wild type αIIb, or residues 1011-1048 of human 
wild type αV was cloned into a pMAL vector (New England Biosystems) downstream of the malE 
gene.  The fusion protein-encoding vectors were transformed into E. coli BL21Star(DE3), which 
were then grown at 37°C in 1 L of LB, and 1mM IPTG was added to induce over-expression of 
the MBP-α-integrin CT fusion proteins, which continued for 4 hours at 37°C.  The cultures were 
harvested by centrifugation, resuspended in 50 mM HEPES (pH 7.4), 150 mM NaCl, lysed by 
sonication, and then clarified by centrifugation.  The MBP fusion products were purified from the 
lysates amylose resin beads (New England Biolabs) according to the manufacturer’s instructions.  
Samples were dialyzed against 50 mM HEPES (pH 7.4), 150 mM NaCl, 10% (v/v) glycerol 
overnight, tested for purity by SDS PAGE, and final protein concentration was measured using 
the BCA protein assay (Pierce). 
Isothermal titration calorimetry (ITC) – ITC was performed to quantify the thermodynamics 
of binding between CIB1 and α-integrin tail peptides as previously described with minor 
modifications (132).  Purified CIB1 was dialyzed extensively in 50 mM HEPES (pH 7.4), 150 mM 
NaCl, 0.1 mM CaCl2 (unless noted differently elsewhere), and diluted to a concentration of 100 
µM.  Peptides were freshly dissolved to concentrations ranging from 0.8 to 1 mM in the same 
buffer as CIB1.  Isothermal titrations were performed using a MicroCal VP-ITC microcalorimeter.  
Injections of 10 µL of peptide were added at 300 s intervals at either 15 °C or 26 °C.  The heats 
of dilution were estimated from injections made after saturation occurred.  These values were 
subtracted from the data before one-site curve fitting was performed using Microcal, LLD Origin 
7. 
Co-immunoprecipitation – Co-IP was performed to determine whether CIB1 associates with 
αVβ3 or α5β1 integrin complexes in mammalian cells as previously described with some 
modifications (163).  HEK293T cells were maintained in DMEM supplemented with 10% FBS and 
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1% non-essential amino acids at 37 °C and 5% CO2.  Plasmids encoding human integrin α5 or 
αV were transiently transfected in HEK293T cells using Fugene (Roche) according to 
manufacturer’s instructions.  Cells were harvested  and lysed with CHAPS lysis buffer (25 mM 
HEPES [pH 7.4], 150 mM NaCl, 10 mM CHAPS, 30 mM NaF, 10 mM β-glycerophosphate, 0.2 
mM Na3VO4, 1.25 mg/mL N-ethylmaleimide, 0.1 mM CaCl2, 0.1 mM MgCl2, 5% glycerol, and 
Protease Inhibitor Cocktail III (Calbiochem) diluted 1:100).  Clarified lysates were incubated 
overnight with either chicken non-specific or anti-CIB1 IgY, and immune complexes were 
precipitated using goat anti-chicken IgY agarose beads (Aves Labs, Inc.).  Beads were washed 
three times in lysis buffer and eluted with 1X non-reducing sample buffer.  Samples were resolved 
by SDS-PAGE, transferred to PVDF membrane and probed with rabbit anti-integrin α5 polyclonal 
antibody (Millipore), mouse anti-integrin αV monoclonal antibody (BD Transduction) or chicken 
anti-human CIB1 IgY. 
Co-precipitation – Purified recombinant MBP-αIIb or MBP-αV cytoplasmic tails were loaded onto 
amylose resin beads and washed 3x in assay buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 0.1 
mM CaCl2).  MBP-tail beads were added to recombinant WT or mutant CIB1 proteins diluted in 
assay buffer (0.75 mg/ml) and incubated 1 h at 4°C.  Beads were washed 3x with assay buffer 
and samples were analyzed by SDS-PAGE. 
Nanodisc production and pulldown assays – Nanodiscs were generated using a protocol 
developed by the Stephen Sligar Lab (210-212). Phosphatidylcholine (PC) and 
phosphatidylserine (PS) lipids (Avanti Polar Lipids) were dried with nitrogen gas to evaporate 
chloroform. Dried lipids were resuspended in 200mM CHAPS (AppliChem) and stored at 4 °C. 
Nanodisc components were mixed at the following ratios in this order: MSP1 (25 nmol, 5x αIIb); 
lipid (1.625 μmol, 65x MSP1; 90:10 mixture of PC:PS); cholate (14 mM); diluted to final volume 
of 660 μL in TBS (20 mM TRIS, 150 mM NaCl); αIIb peptide (5 nmol). Nanodisc mixtures were 
then rotated with 400 mg Bio Beads SM-2 Adsorbent (Bio-Rad) at 4oC for 2 hours (Bio Beads 
 89 
 
were pre-washed according to manufacturer’s protocol prior to mixing with nanodisc 
components). Samples were then run over Ni2+-NTA superflow (Qiagen) to positively select for 
nanodiscs via His-tagged MSP1, washed 3x with TBS + 30mM imidazole (Sigma), and eluted 
with TBS + 250mM imidazole. Nanodisc-containing samples (determined by absorbance at 
580nm) were pooled and dialyzed against 25mM TRIS + 150 mM NaCl overnight with 2 
exchanges using 10,000 molecular weight cutoff Slide-a-lyzer Dialysis Cassettes (Thermo 
Scientific), then stored at 4 °C.  
Nanodisc pulldown assays were done by mixing 25 μL nanodiscs with 1 μL CIB1 (110 
μg/mL) and diluting with 464 μL TBS-I (20 mM TRIS, 150 mM NaCl, 0.1 mM CaCl2, 30 mM 
imidazole), rotating at room temperature for 5 min, then adding pre-washed Ni2+-NTA (10 μL 
packed beads) and rotating at room temperature for 1 hour. Beads were then washed 2x with 
TBS-I and resuspended in 1x sample buffer (2x sample buffer diluted with 250 mM imidazole) 
and heated at 95  °C to elute proteins, then stored at -20  °C. Samples were analyzed by Western 
blot to qualitatively assess the amount of CIB1 protein that precipitated with the nanodisc/ Ni2+-
NTA beads.  
Electron microscopy – Transmission electron microscopy images of prepared nanodiscs were 
obtained at the UNC Microscopy Services Laboratory to confirm uniform size and shape of 
nanodiscs. We followed a protocol similar to previously published protocols (213). Briefly, samples 
were prepared by discharging carbon grids using a glow discharge system. A drop of sample was 
pipetted onto the grid and allowed to stand, then blotted with a piece of sterile filter paper. The 
grid was then inverted and placed on a droplet of 2% (wt/vol) uranyl acetate briefly, then blotted 
again with filer paper. The grids were then allowed to air dry and then imaged using a Zeiss TEM 
910 Transmission Electron Microscope. 
Size-exclusion chromatography – A Superdex 200 10/300 GL column was used (Sharon 
Campbell lab). Column was washed with 4 column volumes (column volume = 23.562 mL) of 1x 
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TBS (25mM TRIS, 150 mM NaCl, de-gassed). 0.5mL of each sample was loaded into 1mL loop 
using a 1 mL syringe and flowed through column at 0.5 mL/min and washed with 1.5 column 
volumes buffer between each sample. Fractions were collected each minute. The molecular 
weight of the peaks in the column were calculated using the following equation: 
y = 22.88 + (-4.65)(log10MW) 
where y = the elution volume (mL) and MW = the molecular weight in kDa. Appropriate fractions 
were further analyzed by Western blot to confirm the presence of nanodisc proteins (MSP1 and 
MBP-integrin). 
Full-length integrin mutagenesis and expression – Full-length integrin αV was cloned into the 
pLVX_IRES_GFP (generously donated by Dr. Scott Magness, UNC) mammalian expression 
vector. Mutations were made using Quikchange site-directed mutagenesis kit (Agilent 
Technologies) to mutate residues 1011-1012 (LV/AA) and 1011-1014 (LVFV/AAAA) to alanine. 
Purified DNA plasmids were packaged into lentivirus by transfecting HEK293T cells and 
harvesting virus-containing media 2 days post-infection. Target cells (HEK293T and M21L) were 
transduced and GFP fluorescence was used to determine transduction efficiency. Relative 
integrin expression was determined by flow cytometry and Western blotting using integrin αV 
antibody (flow cytometry – Millipore; Western blot – BD Biosciences).  
Adhesion assays – 96-well plates were coated with vitronectin (PeproTech) 1 hour at room 
temperature, then washed with PBS. Wells were then blocked with 10 mg/mL BSA (Celliance). 
M21L-αV WT or mutant cells were detached with PBS-2mM EDTA and counted. 1x105 cells were 
plated per well and the wells were then filled with serum free media. Plates were covered and 
spun 3 min at 400 rpm to force cells to the bottom of the wells. Plates were then incubated 30 min 
at 37 °C, uncovered. The plate was then covered and sealed, inverted, and spun at 740 rpm for 
5 min. The plastic cover was carefully removed and wells were washed 1x with 200 μL PBS, then 
fixed with 100 μL 2% formaldehyde for 20 min at room temperature, washed 1x with 200 μL dH2O, 
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stained with 100 μL .1% crystal violet (Sigma) for 30 min at room temperature, and washed with 
200 μL dH2O. The plate was allowed to air dry, then crystal violet was solubilized by adding 100 
μL 1% SDS per well and shaking the plate at 900 rpm for 10 min at room temperature. The plate 
was then read using a SpectraMax plate reader (Molecular Devices) at 590 nm.  
Proliferation assays – M21L-αV WT/2A/4A cells were plated at a density of 1x105 cells per plate 
and allowed to grow for 3 days, then harvested and counted using hemacytometer. Cell viability 
was determined by trypan blue exclusion (Sigma). Average total number of cells from either five 
(WT, 4A) or three (2A) independent experiments was plotted. 
Cell signaling assays – 12-well plates were coated with 10 μg/mL vitronectin for 1 hour at 37 °C, 
then blocked with 10 mg/mL BSA. M21L-αV WT/2A/4A cells were detached using PBS-2mM 
EDTA and held in suspension for 1 hour at 37 °C with occasional mixing, then 5x105 cells were 
plated per well. Plated cells were lysed after 30/60/180 minutes using CHAPS lysis buffer (10 mM 
CHAPS, 0.1 mM CaCl2, 0.05 mM MgCl2, 20 mM NaF, 10 mM βGP, 0.1 mM pervanadate, 1.25 
mg/mL NEM, 20 mM HEPES, 150 mM NaCl, 5% glycerol). Cell lysates were separated by SDS-
PAGE, transferred to PVDF, and probed with antibodies for pERK (Cell Signaling) and Rac 
(Millipore). Films were scanned and density of bands was assessed using ImageJ. 
All-atom replica exchange discrete molecular dynamics (DMD) – Modeling of CIB1 binding 
to  α5 and αV cytoplasmic tail peptides was performed to test for potential binding interactions 
with CIB1, and those models were compared to a simulation of αIIb binding to CIB1. The model 
of CIB1 used in the simulations was either a homology model of CIB1 based on the ligand-bound 
form of calcineurin B (PDB code: 1DGU) or the solution structure of αIIb-CT-bound CIB1 (PDB 
code: 2LM5) (207).  The structure of αIIb was taken from (PDB code: 2KNC), and α5 and αV 
peptide structures were modeled after the αIIb structure using I-TASSER (214,215).  The starting 
structure of each integrin peptide was placed approximately 40 Å away from CIB1 using the edit 
functions of PyMol (216).  The DMD simulations were performed as described by Dagliyan, et al. 
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(217).  In these simulations the backbone of CIB1 was fixed while all atoms of the peptides were 
free to move with some constraints added to preserve the secondary structure.  The DMD engine 
approximates inter-atomic interactions by discrete square well potentials, and models proteins 
using the united atom representation.  The Van der Waals forces, solvation interactions, and 
electrostatic interactions are modeled in a discretized manner as well.  In replica exchange, a 
simulation is performed in replicate at different temperatures and the structures are exchanged 
between the replicates at regular intervals.  This robust approach allows the engine to more easily 
overcome energy barriers.  The length of each simulation was 106 time units, which is 
approximately 50 ns of real time.  After the DMD simulations were complete, hierarchical 
clustering of the integrin binding conformations were performed using root-mean-square 
distances (RMSD) calculated over all heavy atoms in the peptide, and MedusaScore was used to 
evaluate the energy landscape of the clustered poses (218).  The lowest energy complexes were 
taken from the largest clusters and further refined using MedusaDock to obtain the final structures 
(219).  Images of the models were created using PyMol.  Atom pair contacts made between CIB1 
and the integrin CT peptides were identified in the docking models by finding all residues on CIB1 
that were within 4 Å of any side chain atom on the integrin CT peptide using PyMol. 
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FUTURE DIRECTIONS 
In this dissertation, I have presented experimental evidence and analysis for the role of 
CIB1 in cancer cell biology, and in the molecular interaction between CIB1 and integrin cell 
adhesion receptors. While the present body of work has contributed significantly to understanding 
the roles and functions of CIB1 at the molecular and cellular levels, several new questions have 
also been uncovered. Here I will discuss future directions that may be pursued to further explore 
the role of CIB1 in tumor growth, gene expression, and integrin binding. 
A major finding of this work is that RNAi-mediated depletion of CIB1 from triple negative 
breast cancer tumors results in dramatic tumor shrinkage. This exciting result suggests that drug 
targeting of CIB1 may be a novel method to treat cancer. To test the hypothesis that CIB1 is a 
novel cancer drug target, two major questions need to be answered. First, does CIB1 depletion 
effectively shrink tumors in clinically-relevant tumor models? The two models that should be 
explored are patient derived xenografts (PDX) and/or genetically engineered mouse models 
(GEMM). While the xenograft experiments reported on here (see Chapter 2) provide a solid 
foundation for the in vivo relevance of targeting CIB1, PDX and GEMM TNBC models would 
provide more extensive, clinically-relevant data to address whether CIB1 is a target for cancer 
therapy. Second, what additional cancer subtypes are susceptible to CIB1 depletion? This work 
should be pursued at the cellular level by screening cancer cell lines from different tissue types 
and with varying molecular profiles. Cell lines found to be sensitive to CIB1 depletion should then 
be further explored using in vivo models of cancer. Identification of additional cancer subtypes 
susceptible to CIB1 depletion could broaden the scope of the present work, and also provide 
additional clues to the molecular markers that result in non-oncogene addiction to CIB1 (e.g. 
PTEN loss or elevated pAKT).  
This work represents the first report of a role for CIB1 in the regulation of gene expression. 
Further work is necessary to better understand how CIB1 affects gene expression, particularly in 
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cancer cells. In particular, the following questions should be answered. First, which genes does 
CIB1 affect directly, and which genes does CIB1 affect indirectly? As reported here, more than 
800 genes were differentially expressed following extended CIB1 depletion from MDA-MB-468 
cells. To determine which genes are directly affected by CIB1 depletion, we have proposed a 
series of experiments with our collaborators from the Chuck Perou lab using microarrays to 
examine gene expression changes at varying time points following CIB1 depletion. Informatics 
approaches can then be used to identify groups or families of genes that are affected by CIB1 
depletion. Additional questions can then be explored to determine the mechanism by which CIB1 
regulates gene expression and whether CIB1-dependent gene expression changes are different 
in cancer cells versus normal cells. 
Finally, this dissertation lays the groundwork for future experiments exploring CIB1-
integrin binding and the functional consequences of this interaction. First, it is important to better 
understand the biochemical and biophysical properties of the interaction between CIB1 and α-
integrin cytoplasmic tails. As described in section 3.2.2, future experiments should utilize 
nanodiscs to enable in vitro experiments to understand the binding affinity of CIB1 and integrin in 
the presence of a membrane. Furthermore, nanodiscs could enable solving the NMR structure of 
CIB1 in complex with the integrin cytoplasmic tail, which would provide a wealth of knowledge 
about how CIB1 interacts with membrane-embedded integrin. In addition to in vitro assays, 
additional experiments could be designed to more thoroughly explore the role of CIB1-integrin 
binding on cell biology, including integrin-dependent signaling. It would be particularly interesting 
to explore how this role changes depending on cell type, and varying based on the unique 
repertoire of integrins on a particular cell type.  
The work described here has answered several significant questions regarding CIB1, but 
has also opened new and exciting avenues to pursue in cancer, genetics, biochemistry, and cell 
biology. 
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CONCLUSION 
CIB1 is a multifunctional protein with emerging roles in cancer cell biology. Here I have 
presented experimental evidence for two important functions of CIB1: 1) The role of CIB1 in cell 
survival and tumor growth in triple negative breast cancer; 2) The interaction between CIB1 and 
α-integrin cytoplasmic tails and the role of this interaction on cell biology. 
Due to the significant unmet need for novel targeted therapeutics in TNBC, I explored the 
role of CIB1 in TNBC cell survival and tumor growth. Here I have shown that CIB1 depletion is 
necessary for cell survival in multiple TNBC cell lines in vitro, and TNBC xenograft tumor growth 
in vivo. I further defined cell line characteristics that predict sensitivity to CIB1 depletion, including 
elevated AKT activation status and low PTEN expression. RNA sequence analysis was used to 
demonstrate that CIB1 activates gene programs associated with decreased TNBC survival and 
increased cell death. Importantly, CIB1 expression is not upregulated in breast cancer versus 
normal tissue, and does not correlate with prognosis in TNBC patients. Taken together, these 
data are consistent with the emerging theory of non-oncogene addiction, where a large subset of 
TNBCs depend on CIB1 for cell survival and tumor growth, independent of CIB1 expression 
levels.  
To better understand the role of CIB1 as an integrin binding protein, I pursued an additional 
project to explore CIB1 binding to α-integrin cytoplasmic tails and the functional consequences of 
this interaction. Using biochemical and biophysical techniques including isothermal titration 
calorimetry, in vitro co-precipitation, and co-immunoprecipitation, I identified critical residues in 
the α-integrin transmembrane domain to be essential for CIB1-integrin binding. Using molecular 
modeling, I also characterized residues in the CIB1 hydrophobic pocket necessary for interaction 
with unique α-integrin subunits, which was further validated by in vitro co-precipitation assays. 
Finally, I tested the physiological role of CIB1-integrin binding in cells by expressing mutant 
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proteins in cells and measuring differences in integrin-dependent cell functions. I present 
evidence that CIB1 can interact with integrins in the presence of a cell membrane, and that CIB1-
integrin binding may contribute to normal cell functions, including signaling and proliferation.  
CIB1 is emerging as an essential element in TNBC as well as in integrin biology. The work 
presented herein demonstrates the diversity of CIB1 functions and the critical nature of this protein 
in cell biology.  
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APPENDIX A 
Upregulated Genes 
Gene Name 
log2 Fold 
Change padj 
HMGA2 7.36 0.0E+00 
MYH16 6.66 0.0E+00 
IGFN1 6.54 8.3E-114 
CSF2 6.50 1.8E-168 
IL1RL1 6.08 0.0E+00 
C12orf40 6.05 1.0E-46 
KRTAP2-3 5.83 0.0E+00 
IL24 5.56 6.2E-90 
ESM1 5.43 5.9E-115 
METTL11B 5.07 1.9E-31 
ISM1 5.05 2.7E-153 
KRT37 4.95 5.9E-39 
TMEM200A 4.89 6.2E-36 
MARCH4 4.78 9.9E-74 
SERPINB2 4.77 0.0E+00 
IL8 4.71 0.0E+00 
SPRR3 4.69 0.0E+00 
SPRR1B 4.67 3.0E-289 
HAS2 4.66 2.4E-28 
SHC4 4.66 4.1E-160 
KRT34 4.64 0.0E+00 
SH2D5 4.62 2.5E-96 
CTSE 4.56 1.7E-32 
PRSS3 4.54 5.8E-57 
IL1R2 4.54 1.2E-158 
PTHLH 4.51 2.3E-196 
MYH15 4.47 2.0E-303 
RNASE7 4.39 3.5E-39 
SPRR1A 4.38 3.4E-41 
LPPR5 4.34 2.8E-85 
AGPAT9 4.33 0.0E+00 
CORO2B 4.32 2.2E-92 
IL1B 4.31 6.0E-19 
NCAN 4.30 2.6E-50 
ADAMTS6 4.18 4.8E-25 
ERG 4.17 2.3E-47 
TNFSF18 4.15 2.9E-33 
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NOX3 4.12 1.4E-17 
DKK3 4.11 7.8E-30 
SNCB 4.05 6.6E-53 
FAM83C 4.04 8.6E-19 
LOC100130476 4.00 1.4E-67 
RAB3B 3.97 0.0E+00 
IL13RA2 3.97 9.7E-127 
CD274 3.90 0.0E+00 
SH2D1B 3.89 1.4E-20 
NTNG1 3.86 1.2E-39 
SPOCD1 3.83 0.0E+00 
WNT7A 3.82 2.0E-38 
HEPHL1 3.82 0.0E+00 
LGI2 3.79 1.7E-19 
KHDC1L 3.78 2.9E-31 
FAM25A 3.77 2.4E-127 
SYT14 3.75 1.3E-100 
IL6R 3.71 1.3E-71 
ROBO4 3.71 2.2E-50 
SMOC1 3.70 4.2E-174 
INHBA 3.66 0.0E+00 
ALOXE3 3.66 4.2E-146 
FCRLA 3.66 8.0E-33 
KRT6A 3.65 0.0E+00 
KCNK13 3.65 5.2E-71 
ALPK2 3.61 3.3E-115 
LINC00707 3.58 0.0E+00 
GJB4 3.57 1.6E-111 
FOSL1 3.56 0.0E+00 
ENTPD3 3.56 4.4E-41 
PDCL2 3.53 6.0E-15 
PDCD1LG2 3.52 2.5E-19 
VIM 3.47 0.0E+00 
ADRA1D 3.47 1.6E-169 
SOCS2 3.46 0.0E+00 
CYGB 3.46 5.5E-20 
KPNA7 3.46 0.0E+00 
AREG 3.46 9.9E-17 
LOC728084 3.43 1.3E-16 
FLJ35946 3.40 8.4E-72 
NOG 3.40 1.5E-123 
XIRP1 3.40 1.8E-38 
DPF3 3.38 3.5E-27 
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RGS4 3.37 2.3E-12 
MAOA 3.35 0.0E+00 
ITGA2 3.34 0.0E+00 
LY6K 3.30 0.0E+00 
CES1P2 3.29 3.4E-20 
SOCS2-AS1 3.28 6.9E-22 
GCKR 3.27 5.4E-16 
SP8 3.25 1.4E-153 
LMCD1 3.25 1.2E-154 
PCDH12 3.24 1.8E-33 
CRCT1 3.22 4.5E-25 
IL23A 3.22 1.0E-46 
MUSK 3.22 3.9E-25 
RGS20 3.22 3.5E-219 
NPY2R 3.20 4.9E-10 
PTPRH 3.19 3.3E-221 
AXL 3.19 1.5E-120 
LINC00312 3.17 5.1E-19 
CXCL1 3.17 1.5E-297 
TNFAIP3 3.14 0.0E+00 
FST 3.14 7.8E-117 
MMP1 3.13 3.3E-12 
SYNGR3 3.12 6.3E-79 
SYT13 3.10 3.7E-76 
AKNAD1 3.09 6.9E-21 
SBSN 3.09 2.2E-24 
TRIM54 3.07 6.0E-29 
CLMP 3.06 3.4E-93 
VWA3B 3.06 6.1E-98 
PPBP 3.05 2.1E-09 
TH 3.03 6.9E-14 
BACH2 3.03 7.5E-196 
BMP6 3.02 2.1E-51 
SBK2 3.00 1.7E-09 
SPRR2A 2.99 6.6E-73 
NLRP3 2.99 2.3E-24 
KCTD5 2.98 5.3E-34 
PKIB 2.96 8.0E-126 
CHD5 2.94 6.7E-106 
HPCAL4 2.93 4.6E-18 
SLC22A18AS 2.92 1.8E-68 
DRD2 2.91 7.1E-40 
PDE1C 2.91 1.8E-140 
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CXCL6 2.91 2.7E-08 
PRDM16 2.90 7.8E-12 
TENM3 2.90 1.2E-10 
ITGA5 2.89 0.0E+00 
B3GAT2 2.88 2.0E-08 
PHLDA1 2.88 0.0E+00 
TPTEP1 2.88 4.5E-40 
KRT86 2.88 1.4E-229 
DMRT2 2.88 5.9E-13 
ARNT2 2.87 3.9E-101 
ZEB1 2.87 1.0E-26 
SPINK7 2.86 4.8E-08 
RPA4 2.86 4.9E-25 
SYNE1 2.86 5.8E-157 
TMEM255B 2.86 1.7E-32 
COL15A1 2.84 2.8E-167 
WFDC3 2.84 6.1E-40 
RHEBL1 2.84 5.2E-125 
ASB18 2.83 7.3E-08 
PTPN22 2.81 2.0E-51 
CDSN 2.78 3.5E-139 
LOC256021 2.77 2.5E-22 
PDE4B 2.76 0.0E+00 
ART3 2.76 8.8E-52 
ARID3B 2.75 0.0E+00 
GJB3 2.74 0.0E+00 
SFTA3 2.74 7.4E-08 
TBX2 2.74 2.9E-17 
ELOVL6 2.72 0.0E+00 
SMIM3 2.70 0.0E+00 
NCR3 2.70 3.1E-07 
EMX1 2.70 7.2E-12 
COL13A1 2.69 0.0E+00 
CAMK1G 2.69 3.7E-14 
LOC100287177 2.68 5.7E-12 
IL1RN 2.67 0.0E+00 
LOC152225 2.67 5.5E-89 
LOC100288181 2.66 2.4E-45 
FAM83A 2.64 1.3E-107 
FOXF2 2.64 5.1E-21 
LAMB3 2.63 0.0E+00 
LOC401164 2.63 9.8E-08 
GAL3ST3 2.62 3.6E-10 
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SYT6 2.61 9.1E-30 
TRAF1 2.61 1.2E-54 
COL17A1 2.61 2.7E-92 
LOC646626 2.60 1.2E-21 
CLDN6 2.60 2.3E-15 
CWH43 2.60 4.3E-12 
LOC100128993 2.59 1.0E-06 
CDKN1A 2.59 0.0E+00 
SPRY2 2.59 0.0E+00 
ZNF365 2.59 3.4E-290 
MAPK4 2.59 2.9E-30 
PHYHIP 2.57 3.8E-13 
C1QL2 2.56 1.2E-29 
C6orf15 2.56 2.4E-48 
PPM1K 2.56 8.3E-120 
NLRP10 2.55 1.1E-08 
CSNK1A1P1 2.55 1.1E-07 
KRTAP2-1 2.55 1.6E-06 
FAM3C 2.54 0.0E+00 
C12orf39 2.53 6.4E-13 
LINC00161 2.53 2.0E-06 
C12orf75 2.53 0.0E+00 
DNAJB5 2.52 0.0E+00 
KIAA1755 2.52 2.6E-11 
RPSAP52 2.52 1.0E-06 
FYN 2.50 0.0E+00 
KCNF1 2.50 1.7E-17 
TTC9B 2.49 4.5E-12 
TMEM132E 2.49 1.3E-08 
KRT6B 2.49 0.0E+00 
VSIG2 2.49 3.3E-07 
XIRP2 2.48 3.2E-06 
C6orf7 2.47 1.4E-10 
DOCK10 2.47 2.1E-27 
DCLK1 2.47 8.2E-11 
GJB2 2.47 1.9E-165 
KIF5A 2.45 4.5E-06 
ELOVL4 2.45 0.0E+00 
PBX4 2.45 2.8E-143 
SLC5A1 2.44 0.0E+00 
HMX3 2.44 7.5E-08 
CRLF1 2.44 0.0E+00 
WNT9A 2.43 9.5E-157 
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ISG20 2.43 1.1E-68 
PRTN3 2.42 3.5E-08 
KRTAP3-1 2.42 6.1E-118 
ANKRD1 2.42 0.0E+00 
AKAP12 2.41 3.0E-58 
TAGLN3 2.41 2.0E-06 
PTGFR 2.41 9.9E-18 
IL18 2.41 0.0E+00 
PRSS36 2.40 7.4E-34 
GLIPR1 2.39 1.8E-131 
ANKRD44 2.38 6.2E-62 
AQPEP 2.37 1.2E-08 
MGC32805 2.37 7.5E-13 
CST7 2.36 6.8E-06 
TM4SF4 2.35 3.5E-27 
TULP3 2.35 0.0E+00 
KCNMA1 2.35 9.6E-75 
RNF182 2.35 3.3E-78 
DRAXIN 2.34 7.5E-11 
PLEK2 2.33 1.7E-293 
GRM2 2.33 1.2E-19 
BEST3 2.32 4.1E-15 
DMRT3 2.32 4.2E-07 
LINC00704 2.32 3.3E-233 
GADD45A 2.31 0.0E+00 
TGFA 2.31 0.0E+00 
MUC16 2.31 2.2E-66 
RAB39B 2.31 2.2E-22 
LINC00659 2.31 1.7E-05 
REN 2.31 8.2E-100 
CALML3 2.30 3.7E-06 
GPR87 2.30 5.4E-123 
RORA 2.30 1.1E-40 
PMAIP1 2.30 0.0E+00 
HELT 2.30 1.3E-05 
SERPINE1 2.29 0.0E+00 
EREG 2.28 3.4E-44 
GBX2 2.28 5.4E-20 
ATG9B 2.28 1.1E-10 
LOC286059 2.28 1.1E-07 
TMEM59L 2.28 3.9E-16 
GNG4 2.27 8.5E-80 
GFPT2 2.27 3.4E-109 
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PDZD4 2.27 8.3E-51 
LAMA3 2.26 0.0E+00 
WFDC10B 2.26 2.5E-05 
LDHAL6B 2.26 1.0E-07 
VGF 2.26 2.1E-99 
KRTAP4-12 2.25 1.8E-05 
LINC00675 2.25 4.7E-27 
SPRR2D 2.25 2.1E-07 
FAM5B 2.24 1.5E-76 
PRDM1 2.24 0.0E+00 
TMEM151A 2.24 1.2E-16 
FN1 2.23 0.0E+00 
FAM155A 2.23 2.5E-05 
FGF12 2.23 1.0E-07 
FAM211A 2.22 2.2E-71 
HLX 2.22 1.0E-27 
BMP5 2.22 8.2E-16 
ABL2 2.22 0.0E+00 
ZBED2 2.21 4.9E-130 
TMEM121 2.20 5.1E-21 
CYP27B1 2.20 4.4E-26 
RASGRP3 2.20 1.5E-136 
ESAM 2.20 1.3E-139 
CREG2 2.20 3.7E-09 
SLITRK6 2.19 0.0E+00 
LOC100127888 2.19 2.8E-16 
LOC100506178 2.19 9.9E-09 
RCVRN 2.19 3.5E-06 
GPR183 2.19 2.2E-05 
LINC00341 2.18 1.4E-19 
HS3ST1 2.18 1.2E-127 
DUSP14 2.18 0.0E+00 
GAD1 2.18 4.8E-61 
AHRR 2.18 2.0E-191 
ANKRD18DP 2.18 2.4E-11 
PLCXD2 2.18 8.4E-47 
NFATC1 2.18 1.8E-40 
YOD1 2.17 0.0E+00 
ARNTL2 2.17 0.0E+00 
SP9 2.17 3.7E-07 
HOXB5 2.16 1.6E-10 
KAT2B 2.16 8.5E-259 
CTNNAL1 2.16 0.0E+00 
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C1QL1 2.16 4.1E-194 
MRVI1-AS1 2.16 4.9E-06 
KISS1 2.15 8.2E-12 
CYP24A1 2.15 7.7E-07 
GIPR 2.15 3.6E-23 
NOS3 2.15 1.0E-07 
LHX1 2.14 3.1E-66 
FGFRL1 2.14 0.0E+00 
IL10RA 2.14 2.2E-12 
LRRN4 2.13 2.8E-06 
DUSP6 2.13 0.0E+00 
ACVR1C 2.13 2.2E-143 
VSTM1 2.12 2.0E-05 
TMEM55A 2.12 1.9E-35 
GCNT3 2.12 1.2E-69 
AHNAK2 2.11 0.0E+00 
KIRREL2 2.11 1.8E-05 
CRTAM 2.11 2.4E-11 
LAMC2 2.11 0.0E+00 
RNF38 2.11 0.0E+00 
COL4A3 2.11 2.3E-109 
SLC35D3 2.11 3.4E-05 
SDCBP2 2.10 9.8E-47 
ARID3A 2.10 7.1E-231 
SGTB 2.09 0.0E+00 
TSPAN5 2.09 0.0E+00 
LOC256880 2.09 1.1E-13 
HSD3B1 2.09 1.1E-05 
SYT1 2.09 3.4E-20 
HOXB9 2.09 2.0E-13 
C9orf135 2.09 8.0E-07 
C11orf91 2.08 1.0E-14 
SERPINA6 2.08 8.8E-12 
BTBD19 2.08 4.6E-22 
TMEM156 2.08 0.0E+00 
PGF 2.08 2.9E-11 
SEC23A 2.08 0.0E+00 
TINAG 2.07 4.1E-05 
MPZ 2.07 8.8E-06 
ECM1 2.07 1.3E-188 
SERPINE2 2.06 2.8E-142 
DKK1 2.06 0.0E+00 
MMRN2 2.06 1.5E-181 
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MYO1E 2.06 0.0E+00 
PANX2 2.05 1.1E-94 
CCDC3 2.05 4.9E-50 
LINGO1 2.05 9.8E-53 
ANGPT4 2.05 1.4E-07 
IL6 2.05 1.8E-60 
GBP6 2.04 1.8E-12 
STEAP1 2.04 1.9E-09 
DUSP7 2.04 0.0E+00 
CYP4F22 2.04 1.2E-04 
TGFBR3L 2.04 2.3E-34 
GPR1 2.04 3.4E-22 
CDYL2 2.04 2.1E-05 
ROCK1P1 2.03 1.3E-173 
SNX29P2 2.03 1.1E-04 
RNF223 2.03 0.0E+00 
TMEM40 2.03 0.0E+00 
HERPUD1 2.03 0.0E+00 
UPP1 2.03 0.0E+00 
DIRC3 2.02 1.5E-154 
MRVI1 2.02 1.8E-29 
TM4SF19 2.01 1.7E-04 
SKAP1 2.01 1.5E-04 
COL1A2 2.01 1.3E-04 
A2ML1 2.01 2.4E-73 
GEM 2.00 9.6E-32 
CDK15 2.00 6.9E-06 
PPP4R4 2.00 7.4E-07 
AMMECR1 2.00 0.0E+00 
ELK3 2.00 1.9E-293 
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APPENDIX B 
Downregulated Genes 
Gene Name 
log2 Fold 
Change Padj 
CRISP3 -8.32 0.0E+00 
CYP4Z1 -7.00 3.4E-111 
CP -6.89 1.9E-205 
COL3A1 -6.69 3.2E-148 
S100A7A -6.08 2.6E-219 
RARRES3 -5.76 0.0E+00 
SYCP1 -5.66 8.2E-48 
CFI -5.59 8.8E-264 
ANXA10 -5.51 5.4E-44 
CFH -5.49 7.4E-59 
LBP -5.27 1.6E-32 
EDIL3 -5.23 6.4E-92 
FMO6P -5.20 4.0E-36 
CYP4Z2P -5.18 3.6E-31 
GUCY1A2 -5.16 1.2E-122 
TLL1 -5.09 2.3E-38 
BCHE -5.08 1.4E-33 
MMP13 -5.05 5.2E-84 
CYP4B1 -5.04 0.0E+00 
SEPP1 -5.03 5.9E-215 
ATP6V1B1 -5.03 0.0E+00 
SLC27A6 -5.01 1.0E-28 
CHRNA9 -4.88 2.9E-34 
SLURP1 -4.85 4.8E-30 
HRASLS2 -4.84 1.7E-96 
STAC2 -4.80 1.7E-82 
ATP13A5 -4.72 6.2E-205 
PLEKHS1 -4.60 1.1E-163 
ALDH1A1 -4.60 1.0E-78 
HAPLN1 -4.45 2.1E-26 
TENM2 -4.43 3.9E-185 
POF1B -4.41 8.3E-29 
ANO3 -4.41 4.4E-40 
METTL7A -4.36 9.5E-85 
SLC34A2 -4.34 2.5E-104 
TF -4.32 1.5E-28 
ELSPBP1 -4.30 3.6E-22 
PIP -4.25 3.3E-24 
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SYT12 -4.19 0.0E+00 
FAM5C -4.18 2.3E-18 
CTNNA3 -4.16 3.2E-37 
C1orf168 -4.14 3.2E-20 
ADH1C -4.13 4.5E-22 
SLITRK5 -4.10 3.0E-24 
ACY3 -4.09 3.6E-31 
BPIFB1 -4.08 1.2E-56 
NXF3 -4.06 3.7E-25 
LRP2 -4.05 3.0E-22 
PALM3 -4.02 3.7E-59 
C11orf92 -4.01 8.3E-134 
DEFB1 -4.00 5.4E-57 
GABRP -3.98 7.9E-24 
CD34 -3.94 8.4E-53 
AKR1C2 -3.94 0.0E+00 
ALDH3B2 -3.93 0.0E+00 
CLCA2 -3.93 0.0E+00 
TACR1 -3.92 1.8E-31 
LMO3 -3.91 1.7E-18 
COL14A1 -3.91 1.5E-21 
SCIN -3.87 1.5E-64 
RNF128 -3.86 7.6E-69 
ABCC6P1 -3.86 4.2E-17 
RERG -3.85 0.0E+00 
SPINK8 -3.84 1.4E-19 
C8orf4 -3.84 5.0E-16 
IL22RA2 -3.83 2.1E-264 
TRIL -3.81 2.6E-223 
UGT1A6 -3.80 6.7E-33 
MOGAT2 -3.77 6.9E-18 
CXCL17 -3.72 2.1E-16 
SPTLC3 -3.71 1.8E-171 
CCL22 -3.69 0.0E+00 
NKAIN2 -3.69 8.0E-19 
SLC15A2 -3.66 6.1E-215 
TXLNB -3.65 1.5E-16 
CFB -3.62 0.0E+00 
PTPRZ1 -3.62 6.1E-16 
FAIM2 -3.61 1.3E-51 
CXXC4 -3.60 2.3E-14 
ACE2 -3.60 1.7E-125 
SOSTDC1 -3.60 2.6E-26 
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MYL9 -3.59 3.6E-64 
PLA2G4A -3.55 1.5E-15 
CLU -3.54 0.0E+00 
ZG16B -3.52 2.0E-20 
FOS -3.51 1.5E-21 
VCAM1 -3.50 2.2E-22 
EDNRB -3.50 6.7E-22 
ALX1 -3.50 2.9E-12 
BDNF -3.50 1.4E-39 
FAM198B -3.50 3.3E-55 
STK31 -3.49 4.4E-35 
MSX2 -3.49 3.9E-12 
MAGEA4 -3.48 8.8E-15 
SLC51B -3.47 5.4E-12 
THSD7A -3.46 7.4E-110 
MAGED1 -3.45 1.5E-30 
LGR6 -3.44 1.1E-31 
COLEC12 -3.42 1.2E-11 
ALDH3A1 -3.41 4.8E-132 
LINC00478 -3.39 8.6E-20 
LOC100128420 -3.39 2.3E-29 
TBATA -3.37 1.0E-13 
CIB1 -3.36 0.0E+00 
GPRC5B -3.34 5.2E-95 
SHROOM4 -3.31 2.8E-55 
POU2AF1 -3.30 6.8E-28 
TIMP3 -3.30 0.0E+00 
MSMB -3.29 4.0E-24 
SPTSSB -3.29 1.7E-99 
EBF1 -3.27 1.7E-10 
LINC00284 -3.24 4.8E-27 
GRID2 -3.24 2.9E-11 
LRRC31 -3.24 2.9E-13 
LOC285629 -3.22 5.7E-51 
BTN3A3 -3.22 1.8E-88 
MUM1L1 -3.22 6.8E-24 
KRT4 -3.21 0.0E+00 
ALPP -3.20 0.0E+00 
HPGD -3.19 5.4E-21 
RASL11A -3.18 2.0E-78 
PDE11A -3.18 5.7E-106 
KRT38 -3.18 1.1E-14 
TFAP2B -3.17 6.5E-10 
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CAPN9 -3.17 1.3E-13 
PGLYRP4 -3.17 9.7E-20 
SYN3 -3.15 8.0E-10 
MRAS -3.15 0.0E+00 
IGFL1 -3.14 2.9E-164 
RXFP1 -3.14 8.8E-29 
FATE1 -3.13 1.6E-10 
GGT1 -3.12 2.9E-49 
FSTL5 -3.11 3.3E-16 
CPXM1 -3.10 1.1E-11 
AKAP6 -3.09 0.0E+00 
KXD1 -3.08 0.0E+00 
CCDC83 -3.07 2.3E-18 
MMP7 -3.07 7.4E-50 
STMN2 -3.06 3.2E-09 
MEGF10 -3.05 4.0E-136 
PCDH18 -3.04 2.0E-18 
CFTR -3.04 2.0E-09 
C11orf93 -3.04 1.1E-89 
ALPPL2 -3.04 2.0E-32 
IGFBP5 -3.03 0.0E+00 
RASL10B -3.02 6.8E-40 
CYP4X1 -3.02 0.0E+00 
PCDHA1 -3.00 7.0E-09 
KLHDC3 -3.00 0.0E+00 
ARHGAP42 -3.00 1.7E-27 
GPD1 -2.99 6.1E-19 
MUC15 -2.99 3.2E-302 
AK7 -2.97 1.0E-12 
TTC30A -2.97 3.1E-120 
SLC16A7 -2.96 1.3E-10 
BBOX1 -2.95 6.3E-110 
NRK -2.94 2.5E-146 
TLR3 -2.94 8.6E-88 
RGL1 -2.94 9.1E-276 
RUFY4 -2.93 3.9E-09 
C1S -2.92 2.5E-19 
FMO3 -2.92 5.0E-09 
ZNF275 -2.92 2.0E-08 
CPED1 -2.91 8.1E-19 
WDR52 -2.90 6.8E-91 
CRISP2 -2.90 2.6E-08 
SPATA17 -2.90 4.1E-14 
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NPY1R -2.88 1.9E-35 
ZSCAN4 -2.88 7.6E-29 
ESPN -2.86 7.6E-91 
FOSB -2.86 6.0E-173 
CCDC85A -2.86 4.5E-08 
MYOT -2.85 3.5E-27 
TNNC1 -2.83 4.6E-83 
LINC00277 -2.83 1.9E-08 
SV2C -2.82 7.1E-08 
HTR2C -2.82 2.1E-08 
ERP27 -2.81 4.9E-229 
RARRES1 -2.80 0.0E+00 
ATP10B -2.80 1.4E-46 
LIPK -2.79 2.0E-11 
PTGER3 -2.79 3.3E-28 
ZMAT4 -2.79 1.3E-08 
CPAMD8 -2.79 7.4E-192 
CD180 -2.78 4.9E-12 
PIGR -2.77 7.0E-23 
LOC283335 -2.77 1.4E-42 
FOXI1 -2.77 0.0E+00 
ZNF385D -2.77 8.0E-08 
CATSPERB -2.75 1.7E-16 
CHST4 -2.75 3.7E-11 
DNM3OS -2.74 2.0E-10 
OMA1 -2.74 1.2E-281 
RIMS1 -2.73 4.4E-87 
SIDT1 -2.73 1.7E-70 
FGG -2.72 1.5E-40 
CPVL -2.72 6.9E-149 
MGP -2.71 0.0E+00 
PBX1 -2.71 0.0E+00 
S100A7 -2.71 0.0E+00 
CCL2 -2.70 4.2E-22 
AKR1C1 -2.70 6.2E-56 
TMCO5A -2.68 1.2E-07 
BCAT1 -2.68 1.7E-35 
KCNB1 -2.67 1.3E-140 
WDR64 -2.67 1.3E-73 
KIF6 -2.66 7.1E-09 
VWA5A -2.66 4.0E-61 
ZNF711 -2.66 1.9E-09 
PCDHA11 -2.64 3.2E-14 
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TLR5 -2.64 1.4E-97 
METAP1D -2.64 6.9E-46 
PCDH19 -2.63 1.1E-51 
ZNF385B -2.63 3.4E-08 
C10orf107 -2.63 2.9E-07 
TMEM150A -2.62 6.7E-108 
PLCH1 -2.62 2.6E-89 
PRLR -2.61 0.0E+00 
SVOPL -2.61 1.1E-09 
CAB39L -2.61 6.3E-82 
LOC100129534 -2.60 2.7E-27 
CLDN10 -2.60 1.8E-142 
PPM1H -2.60 1.7E-142 
PIR -2.60 8.5E-56 
SEMA3G -2.59 1.0E-33 
ZNF804A -2.59 3.9E-17 
EPHX2 -2.58 8.0E-31 
DNAJC30 -2.56 1.7E-70 
ALMS1P -2.55 1.0E-06 
SBSPON -2.54 1.7E-37 
UNC5C -2.54 1.7E-22 
CNGA2 -2.54 9.7E-07 
GULP1 -2.52 4.1E-16 
A2M -2.52 0.0E+00 
SIAE -2.52 2.1E-104 
CCDC160 -2.51 3.7E-74 
PDZK1IP1 -2.51 0.0E+00 
KIT -2.51 7.6E-11 
IGF2BP1 -2.50 6.8E-10 
TTC12 -2.49 6.3E-195 
BST2 -2.48 8.1E-100 
SLC7A2 -2.48 8.3E-09 
CXCL10 -2.48 8.1E-07 
PPFIBP2 -2.47 8.7E-159 
CTGF -2.46 8.8E-136 
CRABP1 -2.46 6.4E-08 
COL26A1 -2.46 1.3E-25 
HSPB7 -2.45 6.2E-12 
CRABP2 -2.44 0.0E+00 
DUSP27 -2.43 1.0E-10 
LOC100505695 -2.43 1.9E-07 
CNTN5 -2.43 5.1E-06 
DIXDC1 -2.43 6.4E-268 
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EDAR -2.43 2.7E-12 
AXIN2 -2.43 1.2E-177 
DIRAS2 -2.43 1.4E-11 
DIO2 -2.43 4.8E-91 
SPG20 -2.43 3.0E-18 
AKR1C3 -2.42 1.9E-12 
CASP14 -2.42 0.0E+00 
GSTP1 -2.42 1.6E-45 
CAPN13 -2.41 0.0E+00 
SERPINB4 -2.40 6.6E-46 
CXorf57 -2.40 2.3E-14 
DAPL1 -2.40 1.0E-37 
FAM107A -2.39 4.0E-06 
ZNF648 -2.38 8.3E-06 
DNAJC12 -2.38 4.0E-16 
C2orf66 -2.37 4.4E-08 
DZIP3 -2.36 1.4E-150 
BDH2 -2.36 4.4E-109 
MUCL1 -2.36 9.8E-06 
TMC4 -2.36 1.4E-98 
PTGIS -2.36 5.1E-34 
NRAS -2.36 0.0E+00 
SPRR2B -2.36 5.8E-06 
IFI44L -2.35 3.4E-07 
C3 -2.35 0.0E+00 
C10orf71 -2.35 1.1E-05 
OXGR1 -2.35 9.4E-10 
LINC00158 -2.35 1.1E-05 
TMEM133 -2.35 5.6E-07 
PDE7B -2.35 7.4E-13 
CD14 -2.34 2.5E-11 
USH2A -2.34 9.4E-07 
EGOT -2.34 5.6E-12 
VTCN1 -2.34 0.0E+00 
SPA17 -2.34 2.8E-29 
CDH2 -2.33 5.3E-16 
C11orf65 -2.33 3.8E-10 
LMO1 -2.33 3.4E-22 
AADAC -2.33 4.0E-06 
RDH10 -2.32 0.0E+00 
LIPA -2.32 0.0E+00 
FAM227B -2.32 3.1E-12 
MNF1 -2.31 0.0E+00 
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WDR78 -2.31 4.4E-45 
THNSL1 -2.31 2.8E-65 
MUC20 -2.30 7.0E-57 
KLHL3 -2.30 2.5E-15 
PLA2G16 -2.29 3.9E-185 
SNAPC5 -2.29 3.8E-57 
KCNK5 -2.29 0.0E+00 
C14orf101 -2.28 2.2E-252 
KIF26B -2.28 3.6E-08 
LOC401109 -2.27 9.2E-27 
SYCE3 -2.27 6.6E-06 
ERMAP -2.27 1.9E-217 
PCDH8 -2.27 5.4E-16 
C20orf202 -2.27 2.3E-05 
ADAMTS15 -2.27 2.2E-10 
MAT1A -2.27 2.3E-40 
CDH13 -2.26 1.7E-05 
EFCAB6 -2.26 3.1E-08 
FAM86C2P -2.26 8.3E-45 
CASC1 -2.26 8.7E-08 
LMAN2L -2.26 1.4E-124 
PI3 -2.26 2.2E-46 
SELENBP1 -2.26 1.7E-114 
GPR12 -2.26 1.4E-18 
TP53TG1 -2.25 3.6E-20 
LOC254559 -2.25 3.7E-65 
STAB2 -2.25 7.7E-18 
FOLR1 -2.24 4.4E-28 
LDLRAD4 -2.24 3.5E-133 
UPB1 -2.24 4.5E-19 
ABCC11 -2.23 2.2E-08 
CR2 -2.23 1.3E-18 
BCMO1 -2.23 1.5E-17 
REG1B -2.23 3.3E-05 
SCN2A -2.22 7.4E-07 
SEMA3E -2.22 4.7E-239 
FMO2 -2.22 8.0E-07 
TMEM52B -2.22 2.8E-43 
SLC2A4 -2.22 2.9E-13 
MYO16 -2.22 6.3E-11 
SPEF2 -2.21 2.9E-53 
LOC339874 -2.21 7.2E-06 
ACN9 -2.21 1.1E-56 
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LOC100288842 -2.20 3.5E-10 
LOC285419 -2.20 1.4E-05 
COL8A1 -2.20 1.8E-06 
CLCNKA -2.20 8.8E-11 
ARSD -2.20 2.0E-304 
XCR1 -2.20 3.8E-05 
LDHD -2.19 2.2E-09 
FMO5 -2.19 1.7E-24 
ST6GALNAC4 -2.19 1.6E-15 
FSIP2 -2.19 5.4E-11 
FMO9P -2.19 1.7E-05 
SAMD15 -2.18 2.4E-13 
CCDC113 -2.18 6.5E-136 
SOX5 -2.18 4.9E-05 
TNS1 -2.18 0.0E+00 
DENND2D -2.18 9.2E-270 
LOC643733 -2.18 1.1E-13 
IFIT1 -2.18 2.5E-16 
ID1 -2.18 9.4E-205 
UMODL1 -2.17 8.3E-06 
NPR1 -2.17 1.0E-07 
NPY5R -2.17 3.2E-05 
RBBP8NL -2.16 1.0E-64 
ANTXR1 -2.16 0.0E+00 
SAA2 -2.16 6.9E-55 
GLYATL2 -2.16 0.0E+00 
C6orf165 -2.16 1.0E-23 
OLFM4 -2.16 0.0E+00 
PNMT -2.16 4.4E-05 
LOC100506668 -2.15 5.5E-69 
VGLL1 -2.15 0.0E+00 
CASP1 -2.15 5.7E-45 
KTN1-AS1 -2.14 6.2E-12 
CTNNA2 -2.14 4.8E-05 
OGDHL -2.14 1.8E-12 
SORBS2 -2.14 3.1E-15 
ZBTB7C -2.14 5.7E-152 
WNT4 -2.14 3.0E-100 
SDSL -2.14 2.3E-52 
GPM6A -2.14 2.6E-05 
FBXO15 -2.14 7.0E-05 
TSC22D3 -2.14 6.1E-21 
ZNF454 -2.13 8.7E-35 
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HS6ST3 -2.13 1.4E-50 
CCDC89 -2.13 3.1E-05 
SERPINA3 -2.13 0.0E+00 
S100A7L2 -2.13 1.0E-05 
KIAA1324 -2.13 1.5E-08 
SCPEP1 -2.13 0.0E+00 
PPP1R1B -2.13 4.9E-23 
USH1G -2.12 1.4E-06 
MYO3B -2.12 9.3E-36 
CCR2 -2.12 4.0E-06 
SAMD11 -2.12 2.0E-21 
LOC100505776 -2.12 5.6E-11 
RPP25L -2.12 1.7E-171 
CLIC3 -2.12 2.4E-07 
UPK2 -2.12 2.8E-15 
GRAMD1C -2.11 2.1E-83 
LOC283194 -2.11 1.3E-12 
LOC153684 -2.11 1.2E-07 
AQR -2.11 0.0E+00 
GSTA4 -2.11 4.9E-31 
DMGDH -2.10 3.6E-10 
PRODH -2.10 4.0E-281 
ABCC6P2 -2.09 5.0E-05 
ACTL8 -2.09 4.7E-05 
HFE -2.09 1.8E-73 
CETP -2.08 1.0E-04 
PALMD -2.08 1.6E-146 
C7orf63 -2.08 8.5E-11 
POLR3GL -2.08 3.0E-78 
CCDC11 -2.08 3.7E-07 
PKI55 -2.08 3.5E-40 
CHRDL1 -2.07 7.6E-17 
C9orf116 -2.06 1.3E-25 
SNHG4 -2.06 5.5E-37 
GUCY1A3 -2.06 0.0E+00 
CCDC25 -2.06 0.0E+00 
GSTA1 -2.06 9.0E-13 
C12orf66 -2.06 3.8E-36 
HCG26 -2.06 6.7E-10 
C1orf192 -2.05 9.4E-33 
LOC284344 -2.05 3.5E-13 
CALCRL -2.05 3.5E-05 
C17orf97 -2.05 8.7E-62 
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TMPRSS12 -2.05 1.3E-04 
RBM20 -2.04 3.3E-05 
LOC100132078 -2.04 1.5E-04 
BSND -2.04 2.2E-08 
RIC3 -2.04 1.8E-05 
NCAM2 -2.03 1.4E-04 
MTHFR -2.03 4.1E-106 
TMED6 -2.02 8.6E-08 
UCP2 -2.02 0.0E+00 
HIST1H2BD -2.02 3.0E-70 
DUSP19 -2.02 1.4E-30 
HSD17B8 -2.02 7.0E-31 
CAPN3 -2.02 7.9E-07 
RCOR2 -2.01 5.5E-35 
C11orf71 -2.01 2.3E-44 
DOC2A -2.01 2.9E-11 
SEC16B -2.01 3.3E-17 
GJC3 -2.01 1.7E-10 
PDGFD -2.00 3.8E-16 
 
  
 117 
 
APPENDIX C 
 
Top 100 gene signatures based on Pearson Correlation with CIB1 KD gene signature. 
Signature 
Pearson 
Correlation 
GSEA.NABA_MATRISOME_ASSOCIATED 0.838 
GSEA.EXTRACELLULAR_SPACE 0.789 
GSEA.KRAS.LUNG.BREAST_UP.V1_UP 0.780 
GSEA.NABA_ECM_REGULATORS 0.778 
GSEA.BMI1_DN_MEL18_DN.V1_UP 0.776 
GSEA.EXTRACELLULAR_REGION_PART 0.774 
GSEA.EXTRACELLULAR_REGION 0.769 
GSEA.VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP 0.765 
GSEA.ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP 0.751 
GSEA.BMI1_DN.V1_UP 0.748 
GSEA.MODULE_220 0.741 
Luminobasal.IncreasedGenes.Haughian 0.738 
GSEA.MEL18_DN.V1_UP 0.738 
GSEA.ORGAN_DEVELOPMENT 0.735 
GSEA.NABA_SECRETED_FACTORS 0.735 
GSEA.MODULE_433 0.727 
GSEA.TGANTCA_V$AP1_C 0.726 
GSEA.LEF1_UP.V1_UP 0.726 
GSEA.MULTICELLULAR_ORGANISMAL_DEVELOPMENT 0.725 
GSEA.SYSTEM_DEVELOPMENT 0.724 
GSEA.MODULE_324 0.723 
GSEA.PLASARI_TGFB1_TARGETS_10HR_UP 0.721 
GSEA.KRAS.600.LUNG.BREAST_UP.V1_UP 0.721 
GSEA.HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS 0.720 
GSEA.ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP 0.718 
GSEA.PTEN_DN.V2_UP 0.716 
GSEA.PRC2_EZH2_UP.V1_DN 0.712 
GSEA.HALLMARK_KRAS_SIGNALING_UP 0.711 
GSEA.MODULE_122 0.709 
GSEA.ANATOMICAL_STRUCTURE_DEVELOPMENT 0.708 
GSEA.KRAS.600_UP.V1_UP 0.706 
GSEA.TGFB_UP.V1_UP 0.703 
GSEA.WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 0.702 
GSEA.MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3 0.701 
GSEA.GSE17721_PAM3CSK4_VS_GADIQUIMOD_1H_BMDM_UP 0.699 
GSEA.VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN 0.698 
GSEA.CELL_MIGRATION 0.698 
GSEA.PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN 0.698 
GSEA.MODULE_248 0.696 
GSEA.LIM_MAMMARY_STEM_CELL_UP 0.691 
GSEA.WANG_MLL_TARGETS 0.691 
GSEA.HALLMARK_COAGULATION 0.690 
GSEA.SERVITJA_ISLET_HNF1A_TARGETS_UP 0.689 
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GSEA.MODULE_33 0.689 
GSEA.MODULE_444 0.688 
GSEA.ISSAEVA_MLL2_TARGETS 0.687 
GSEA.CORRE_MULTIPLE_MYELOMA_UP 0.685 
GSEA.CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN 0.684 
GSEA.KRAS.BREAST_UP.V1_UP 0.683 
GSEA.MODULE_112 0.680 
GSEA.GSE360_CTRL_VS_L_DONOVANI_DC_DN 0.680 
GSEA.SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1 0.680 
GSEA.GSE360_L_MAJOR_VS_T_GONDII_MAC_UP 0.679 
GSEA.LINDVALL_IMMORTALIZED_BY_TERT_DN 0.679 
GSEA.P53_DN.V2_UP 0.679 
GSEA.DELYS_THYROID_CANCER_UP 0.677 
GSEA.CROMER_TUMORIGENESIS_UP 0.675 
GSEA.PID_FRA_PATHWAY 0.675 
GSEA.ESC_V6.5_UP_EARLY.V1_DN 0.674 
GSEA.HUANG_DASATINIB_RESISTANCE_UP 0.674 
GSEA.LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP 0.673 
GSEA.GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP 0.672 
GSEA.KRAS.LUNG_UP.V1_UP 0.672 
GSEA.YAMASHITA_METHYLATED_IN_PROSTATE_CANCER 0.671 
GSEA.PID_UPA_UPAR_PATHWAY 0.671 
GSEA.MODULE_362 0.670 
GSEA.MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN 0.670 
GSEA.ORGAN_MORPHOGENESIS 0.670 
GSEA.WANG_METHYLATED_IN_BREAST_CANCER 0.669 
GSEA.JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP 0.669 
GSEA.NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_UP 0.668 
GSEA.MODULE_64 0.667 
GSEA.PTEN_DN.V1_DN 0.667 
Troester.Wound.Signature 0.664 
GSEA.PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2 0.663 
GSEA.VALK_AML_CLUSTER_9 0.663 
GSEA.PETROVA_PROX1_TARGETS_DN 0.660 
GSEA.GNF2_MMP1 0.660 
GSEA.GSE36392_TYPE_2_MYELOID_VS_MAC_IL25_TREATED_LUNG_UP 0.660 
GSEA.MODULE_289 0.659 
GSEA.MODULE_488 0.659 
GSEA.CRX_DN.V1_DN 0.659 
GSEA.MODULE_164 0.659 
GSEA.RECEPTOR_BINDING 0.658 
GSEA.WOO_LIVER_CANCER_RECURRENCE_UP 0.658 
GSEA.RESPONSE_TO_EXTERNAL_STIMULUS 0.658 
GSEA.MODULE_178 0.657 
GSEA.LABBE_TGFB1_TARGETS_UP 0.656 
GSEA.BILD_HRAS_ONCOGENIC_SIGNATURE 0.655 
GSEA.PHONG_TNF_RESPONSE_VIA_P38_PARTIAL 0.654 
GSEA.GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_12H_ACT_CD4_T
CELL_DN 0.654 
GSEA.GSE22886_NAIVE_CD8_TCELL_VS_NEUTROPHIL_DN 0.654 
GSEA.V$AP1_Q2 0.653 
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GSEA.CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN 0.653 
METAPLASTIC.Up 0.652 
GSEA.MODULE_12 0.652 
GSEA.NAKAMURA_ADIPOGENESIS_EARLY_DN 0.652 
GSEA.GSE6269_HEALTHY_VS_E_COLI_INF_PBMC_DN 0.652 
GSEA.HUANG_FOXA2_TARGETS_DN 0.652 
GSEA.LINDGREN_BLADDER_CANCER_CLUSTER_2B 0.651 
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